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“When you have exhausted all possibilities, remember this - you haven't” 
- Thomas A. Edison 
 
ABSTRACT 	  
Immune activation comprises multiple biological checkpoints to ensure proper 
and regulated effector functions. Phagocytes such as macrophages, dendritic 
cells and neutrophils have important functions during inflammation, e.g. 
clearance of bacterial pathogens.  
In this thesis, I have studied the regulatory properties of phagocytes 
and their crosstalk with adaptive immunity has been studied. Their role in the 
regulation of the adaptive immune system has been investigated at the site of 
inflammation and in the initiation of the immune response in the secondary 
lymphoid organs. Different animal models have been used to understand the 
regulatory properties of phagocytes in the context of autoimmunity and 
chronic inflammation. 
We have shown that M2 macrophages can regulate and suppress 
autoimmunity in murine models of both type 1 diabetes and experimental 
autoimmune encephalomyelitis (EAE). The M2 macrophages were localized 
in the targeted organ and had the ability to suppress T cell activation and 
produce factors that promote wound-healing. Furthermore, we identified TGFβ 
as an important cytokine for the immunosuppressive properties of M2 
macrophages, and also a crucial factor in the deactivation of inflammatory 
monocyte-derived cells during EAE remission.  
We have also studied the role of neutrophils in the regulation of 
adaptive immunity in lymph nodes. We generated a neutropenic mouse model 
and studied how neutrophils interacted with T and B cells during adjuvant-
induced inflammation. These studies revealed that neutrophils have an 
immense role in the activation of B cells and the generation of antibody-
producing plasma cells. 
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1 Introduction 
1.1 The immune system 
he immune system has evolved to protect the host from invading 
pathogens such as bacteria and viruses through use of a large number 
of mediators such as recognition and activation receptors1. The immune 
system is also important for host homeostasis through removal of apoptotic 
cells2,3, tissue remodeling and tissue repair4,5. One key aspect of the immune 
system is to discriminate between host molecules, also known as self, and 
molecules derived from potentially dangerous pathogens, defined as non-
self6. Due to the immense cytotoxic and bactericidal properties of certain 
immune cells, the immune system has many built-in regulatory elements and 
checkpoints to control immune activation. Immune cells are broadly divided 
into two large functional groups, the innate immune system and the adaptive 
immune system1. The innate system, which is rapidly activated and has a 
broad but less specific capacity to recognize pathogen-derived molecules, is 
one of the first barriers that the pathogens will encounter. Conversely, the 
adaptive immune system is slower in its activation but is more specific and 
effective in the determination of pathogen-specific targets, and also has the 
unique capacity to develop immunological memory. The innate and adaptive 
immune systems work in a well-balanced symbiosis and communication 
between innate and adaptive immune cells is essential for proper immune 
function.  
 
1.1.1 Innate immune system 
The innate immune system is the first line of defense against invading 
pathogens. The first protection is the physical barrier built up by epithelium 
cells in our skin and mucosal surfaces7. Not only providing a barrier for the 
host, epithelium cells furthermore contribute to the innate immune system by 
producing anti-microbial peptides and molecules. Another passive part of 
innate immunity is a system of circulating plasma proteins termed the 
complement system8. These elements can directly bind to pathogens and 
alarm the immune system by recruiting local and blood-derived innate 
immune cells, facilitating phagocytosis or inducing direct lysis of the pathogen. 
T 
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The earliest recruited immune cells are professional phagocytes, cells that 
actively engulfs extracellular content, including neutrophils, monocytes, 
macrophages, mast cells and dendritic cells (DC)9. Their primary role is to 
mediate uptake and lysis of the pathogens but also to produce inflammatory 
mediators such as cytokines and chemokines. The DCs have the ability to 
migrate to secondary lymphoid organs where they present antigens to the T 
cells of the adaptive immune system10. The recognition of pathogens, or of 
their pathogen-associated molecular patterns (PAMPs), by innate immune 
cells occurs through germline-encoded pattern recognition receptors (PRR) 
such as the Toll-like receptors (TLR) and the C-type lectin receptors (CLR)11. 
Innate cellular activation by PRRs is crucial for the later activation of the 
adaptive immune system. 
 
1.1.1.1 Neutrophils 
The neutrophilic granulocytes, commonly known as neutrophils, are the most 
abundant white blood cells in humans. Neutrophils are short-lived cells, 
spanning from hours to 5 days and are generated and fully differentiated from 
granulocyte-macrophage progenitors in the bone marrow (BM) before being 
released into the circulation12-14. The growth factor granulocyte-colony 
stimulating factor (G-CSF) is important for the activation and release of 
neutrophils from the BM but it is not crucial for neutrophil generation as G-
CSF gene deleted mice are indeed neutropenic in the blood but still generate 
neutrophils in the BM15. During maturation in the BM neutrophils form 
intracellular granules (secretory granules) that contain proteins important for 
their anti-microbial functions16. Upon tissue infection endothelial cells, 
epithelial cells, monocytes and macrophages secrete agents such as G-CSF, 
KC (CXCL1) and MIP-2 (CXCL2) which are key chemokines for neutrophil 
attraction to the site of infection. Neutrophil activation by PRRs induces 
cytokine secretion and phagocytosis of the microorganism. The phagosome 
will fuse with the intracellular granules containing reactive oxygen species 
(ROS) and other noxious agents resulting in the elimination of the pathogen. 
In addition to intra-phagosomal killing, neutrophils have the ability to release 
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their nuclear content into the extracellular matrix and to prevent microbial 
growth, a mechanism termed neutrophil extracellular trap formation17. 
Neutrophils have historically been considered as suicidal killers with limited 
immune functions except for their antimicrobial abilities. It has always been 
challenging to study them in vitro due to their very limited survival. During the 
last decade our knowledge about neutrophils has increased dramatically due 
to the use of more sophisticated research tools. Several reports indicate their 
complex interactions with other innate cells such as macrophages18 and NK 
cells19, but also their ability to interact at the bridge between innate and 
adaptive immunity20, by regulating the antigen-presenting capacity of DC and 
macrophages21 or directly regulating T cell activation22. Neutrophils also 
interact with B cells and are an important source for B cell activating factor 
(BAFF)23.  
 
1.1.1.2 Monocytes 
Monocytes are important innate cells that mostly reside in the blood but also 
have reservoir pools in the lungs and the spleen24,25. They represent about 
5% and 10% of the nucleated cells in mouse and human blood, respectively. 
Monocytes are generated in the BM and the growth factor macrophage-colony 
stimulating factor (M-CSF) is crucial for their differentiation and survival, as 
mice deficient in M-CSF or its receptor M-CSFR demonstrate severe 
monocytopenia26,27. The release of monocytes from the BM is dependent on 
chemokine C-C motif ligand 2 (CCL2), but it is also important for the attraction 
of monocytes to the site of inflammation28.  
There are two types of monocyte subsets in mouse and human blood, 
named inflammatory monocytes and resident monocytes (Table 1). It is 
believed that resident monocytes are generated from inflammatory monocytes 
in the circulation and not from monocyte precursors in the BM29. As for their 
function, inflammatory monocytes are important precursors for tissue 
infiltrating inflammatory macrophages and monocyte-derived DCs (moDC) 
during infection or tissue trauma30,31. Recent reports have revealed interesting 
findings using intravital microscopy regarding resident monocytes; 
demonstrating that these cells crawl along the luminal side of the endothelium 
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wall and patrol for tissue injury in both mice and humans32,33. Taken together, 
monocytes are the source for inflammatory phagocytes during infections and 
tissue trauma, whereas tissue resident phagocytes are believed to be 
important for tissue homeostasis and repair34.  
 
Table 1 | Monocyte subsets in mice and humans 
Mouse monocytes Human counterpart Source Function 
Inflammatory monocytes 
CCR2+Ly-6ChiCX3CR1low CD14
+CD16- Precursor in BM 
Precursors for 
inflammatory 
macrophages and DCs 
Resident monocytes 
CCR2-Ly-6C-CX3CR1hi CD14
+/midCD16+ Ly-6C
hi 
monocytes  
Patrolling the endothelial 
wall 
 
1.1.1.3 Macrophages 
Macrophages are tissue-resident phagocytes that can be found in almost 
every organ (Fig. 1). Macrophages not only act as sentinels surveying the 
local environment for unwanted microorganisms, but they are also important 
cells for tissue homeostasis by engulfing apoptotic cells and secreting growth 
factors35. For example, red pulp macrophages in the spleen are important for 
engulfing dying erythrocytes36, or alveolar macrophages for assisting in the 
removal of allergens in the lungs37. Macrophage functions are adapted to their 
organ residency and are known to be plastic as the environment can 
drastically change. It has for a long time been believed that all tissue-resident 
macrophages are replenished by circulating monocytes throughout life, but 
this dogma has been challenged and rewritten by recent discoveries38.  
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Figure 1 | Macrophage distribution in the human body. Macrophages are found in almost 
every organ throughout the body, where they have many functions such as nursing the tissue 
by secretion of growth factors but also immunosurveillance, including phagocytosis, secretion 
of anti-bacterial molecules and antigen presentation. 
Tissue macrophages can arise prenatally, in adulthood or both depending on 
the population analyzed (Fig. 2). Macrophages can be derived from three 
different sources: the prenatal yolk sac, the prenatal fetal liver or from 
postnatal BM monocytes (Table 2). For example, the central nervous system 
(CNS) resident macrophages, microglia, are purely derived from the yolk sac, 
whereas red pulp macrophages are derived from the prenatal fetal liver. 
Macrophages in the adult liver, the Kupffer cells, originate from the yolk sac or 
fetal liver and are locally maintained independently from BM monocytes 
during adulthood34,38,39. Monocytes give rise to tissue macrophages during 
inflammation but are also important for the replenishment of macrophages in 
some specific organs such as the tissue-resident macrophages in the 
intestine. 
Microglia 
Alveolar macrophages (lung) 
Kupffer cells (liver) 
Intestinal macrophages 
Osteoclasts (bone marrow) 
Splenic macrophages 
Langerhans cell (skin) 
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Figure 2 | Origin of macrophage populations. Macrophages can arise from the yolk sac, 
fetal liver or the adult bone marrow in mice. These macrophages will seed different organs 
during development. Some tissue macrophages will be dependent on mature monocytes from 
the postnatal bone marrow whereas other populations will be locally maintained in the tissue. 
There are several important growth factors for generating and maintaining 
tissue-resident macrophages and monocyte-derived tissue macrophages. 
Studies in mice have revealed that M-CSF, GM-CSF and interleukin (IL)-34 
are important growth factors for different types of tissue macrophages. For 
instance, M-CSF deficient mice are as mentioned earlier monocytopenic, but 
also lack kidney, peritoneal and intestine macrophages40. Interestingly, M-
CSF receptor (M-CSFR) deficient mice demonstrate significant differences 
with the additional loss of skin Langerhans cells and CNS microglia. This 
phenomenon was later demonstrated to be dependent on the alternative 
ligand for M-CSFR, the cytokine IL-3441,42. Studies of irradiated chimeric mice 
and gene-deleted mice revealed the important function of granulocyte 
macrophage-colony stimulating factor (GM-CSF), as these mice lacked lung 
macrophages and developed alveolar proteinosis43. Collectively these studies 
demonstrate the heterogeneity and plasticity of macrophage generation and 
function.  
All tissue resident macrophages have common functions in immune 
surveillance, detection and phagocytosis of pathogens and in alarming the 
tissue. Macrophages can detect microorganisms via the various types of 
PRRs they express, which leads to phagocytosis. Pathogens are trapped in 
the phagosome that will later be fused with lysosomes containing enzymes 
Development 
Yolk sac 
Fetal liver 
Bone marrow 
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and free radicals that will digest and eliminate the pathogen35. Activated 
macrophages will also produce mediators such as inflammatory cytokines and 
chemokines that will attract more immune cells44. Another capacity of some 
tissue macrophages is to locally present antigens from engulfed pathogens to 
recruited cells from the adaptive immune system, in particular to T cells45. 
There is an intimate cross-talk between macrophages and T cells involving 
both receptors and cytokines that will in turn affect cellular and functional 
effector programs of both cell types46,47. In addition to many functions of 
macrophages in innate immunity, they also conduct important roles at the 
bridge between innate and adaptive immunity and are a key effector cell 
during inflammatory responses.  
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       Table 2 | Macrophage ontogeny 
 
Organ Cell type Origin 
Brain Microglia Yolk sac 
Skin Langerhans cells Dermal macrophages 
Yolk sac + fetal liver 
Bone marrow 
Liver Kupffer cells Yolk sac + fetal liver 
Heart CCR2- macrophages CCR2+ macrophages 
Yolk sac + fetal liver 
Bone marrow 
Lung Alveolar macrophages CD11b+ macrophages 
Fetal liver 
Unknown 
Kidney Kidney macrophages Fetal liver or bone marrow 
Spleen Red pulp macrophages Marginal zone macrophages 
Fetal liver 
Unknown 
Peritoneum Peritoneal macrophages Fetal liver 
Intestine Intestinal macrophages Bone marrow 
Blood Monocytes Bone marrow 
 
1.1.1.4 Dendritic cells 
The DCs have many similarities to macrophages and it has historically always 
been difficult to distinguish between these two cell types. But per definition 
DCs have three unique innate properties that make them different from 
macrophages: 1) they migrate to secondary lymphoid organs; 2) they are 
professional antigen-presenting cells (APC) with the ability to activate naive T 
cells via the major histocompatibility complex (MHC) class II complex; and 3) 
they have the ability to cross-present antigens via the MHC class I complex10. 
DCs can be subdivided into two major subsets, classical DCs (cDC) and non-
classical DCs, or the more widely used name, moDCs. The cDCs can be 
further subdivided into different subclasses depending on anatomical location 
and specialized functions. In contrast to macrophages, cDCs are short-lived 
with an approximate half-life of 3-6 days. The seeding of cDCs is dependent 
on BM-derived progenitors that are strictly dependent on the growth factor 
fms-like tyrosine kinase 3 ligand (flt3L)48. Recruitment of monocytes to 
lymphoid and non-lymphoid organs is a consequence of inflammation that will 
differentiate moDCs. The moDCs are difficult to distinguish from cDCs as they 
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express similar surface markers, to some degree migrate to lymphoid organs 
and can activate naïve T cells in vitro, but in some circumstances they also 
express monocyte markers such as cluster of differentiation (CD)64 and 
F4/80 in mice49. Monocytes or BM cultured in vitro with GM-CSF generate 
moDCs50; however, GM-CSF deficient mice still develop moDCs, indicating 
that there are other ligands important for moDC generation51. The activation 
of DCs is very similar to macrophages as they express similar PRRs, which in 
turn activates an inflammatory program that includes phagocytosis, antigen 
loading of the MHC molecules, up-regulation of co-stimulatory receptors and 
cytokine secretion.  
 
1.1.2 Adaptive immune system 
To obtain an antigen-specific immune response the innate immune cells 
activate the adaptive immune system. T and B lymphocytes are key cells of 
the adaptive immune system. The generation of these cells occurs in the 
primary lymphoid organs such as the BM and the thymus, but their activation 
follows in the secondary lymphoid organs such as the lymph nodes (LN) and 
spleen. A unique characteristic of the cells of the adaptive immune system is 
their epitope-specific antigen receptors, the T cell receptor (TCR) and the B 
cell receptor (BCR)52. These receptors are generated by rearrangement of 
gene segments and mutations during maturation that induces high 
diversification and specificity. The TCR and BCR are both fundamental for T 
and B cell activation, respectively. These lymphocytes undergo positive and 
negative selection during their development and mature in the primary 
lymphoid organs. In simple terms, this is a process to ensure that 
lymphocytes accurately recognize foreign antigens52,53. The activation of T 
cells by the TCR is dependent on the MHC molecule and co-stimulatory 
ligands such as CD80 and CD86 expressed by APCs. B cell activation by the 
BCR is dependent on the tertiary structure of the antigen and cross-linking of 
the BCR. Another important attribute of T and B cells is their ability to induce 
immunological memory, which is the capability of the adaptive immune 
system to respond more rapidly and effectively to pathogens that have been 
previously encountered54. 
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1.1.2.1 T cells 
T cell development proceeds from early common lymphocyte progenitors 
(CLP) in the BM that later become recruited to the thymus for their maturation 
into naïve T lymphocytes. During thymic development T cells undergo gene 
rearrangement and clonal selection, and within the thymus the determination 
of T cell lineage takes place55. T cells can be divided into two subsets, CD4+ T 
helper cells (TH) and CD8+ cytotoxic T cells (TC). The antigen-specific 
activation of CD4+ TH cells in the periphery is primarily dependent on the 
presentation of peptides via the MHC class II molecule and co-stimulatory 
molecules that induce T cell proliferation. Furthermore, the cytokine milieu in 
the microenvironment, contributed by APCs and other stromal cells, is 
important for the differentiation of activated T cells and for their later effector 
functions such as cytokine profile and chemokine receptor expression56. 
Activated TH cells have significant functions both locally in the secondary 
lymphoid organs, and most importantly peripherally at the sites of 
inflammation where they instruct and amplify innate immune cell functions. 
Within the secondary lymphoid organs TH cells assist the activation of B cells 
through CD40-CD40L interaction which is essential for the development of 
antibody-producing plasma cells57. TH cells are also involved in the ‘licensing’ 
of APCs, again dependent on CD40-CD40L, and these can then activate 
naïve CD8+ TC cells58,59. Similar to CD4+ TH cells, primary CD8+ TC cell 
activation is dependent on specific antigen recognition via the MHC class I 
molecule expressed by APCs. The primary role for activated TC cells is to 
establish cell contact with a target cell, recognize the antigen and, if the 
antigen is recognized, to induce apoptosis of the targeted cell. Destruction of 
target cells by TC cells is accomplished by perforin/granzyme-mediated 
apoptosis and FAS-FASL-mediated apoptosis60.  
 
1.1.2.2 B cells 
B cells can be divided into three major subsets, the circulating follicular B 
cells, and the more innate-like B1 and marginal zone (MZ) B cells. Studies in 
mice, and to some degree in humans, have deduced that B1 cells are already 
generated in the fetus and undergo self-renewal in the periphery61,62. B1 cells 
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have less diversified and less specific BCRs that recognize highly conserved 
microbial elements63. The activation of B1 cells is T cell-independent and they 
produce circulating natural antibodies believed to be important for early 
defense prior to the development of postnatal follicular B cells. MZ B cells are 
generated in the spleen 2-3 weeks after birth in mice and after 1-2 years in 
humans64,65. Similar to B1 cells, MZ B cells also express less diversified BCRs 
and are T cell-independent for their activation. The generation and maturation 
of postnatal follicular B cells occurs in the BM and they are primarily derived 
from CLPs. These cells undergo many steps before becoming a mature 
circulating follicular B cell66 (Fig. 3). B cells are activated by soluble or static 
antigen interactions with the BCR. Similar to T cells, B cells need further 
signals for proper activation and clonal expansion, this involves CD40-CD40L 
interactions and cytokines secreted by TH cells and myeloid cells to instruct B 
cell functions and antibody isotype switch.  
 
 
Figure 3 | B cell development. The figure illustrates the development of B cells and 
activation into becoming plasma cells or memory B cells. 
 
1.2 Immune activation and regulation 
The primary role of the immune system is to protect the host from unwanted 
microorganisms. The body tightly regulates the activation of the immune 
system, the balance between induction and resolution of inflammation being 
extremely important for survival of the host due to the potential cytotoxic 
properties of the immune cells. Hence the immune system has a very 
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sophisticated regulation with many checkpoints that control different aspects 
of innate and adaptive immune activation. 
1.2.1 Inflammation 
Inflammation is critical for protecting the host, but is also a key factor in the 
development of many complex states and disorders such as autoimmune 
diseases. Inflammation occurs in two manners: acute inflammation, which can 
be defined as a regulated activation of the immune system with defined 
initiation and resolution phases, and chronic inflammation, which can be 
defined as a dysregulated form of inflammation. Persistent injury, infection or 
prolonged exposure to toxins/antigens, can switch acute inflammation into 
chronic inflammation. 
Acute inflammation is generated when innate cells such as mast cells, 
macrophages and endothelial cells are activated upon tissue trauma, either by 
infection or cellular damage, which activates a cascade of downstream 
effector molecules such as G-CSF, CXCL1, CXCL2, IL-1, IL-6 and tumor 
necrosis factor (TNF)67. This response enhances the local permeability of the 
blood vessels and recruits large numbers of neutrophils and monocytes to the 
site of inflammation9. The increased metabolic activity and enhanced cellular 
recruitment at the local site builds up the five core elements of inflammation, 
heat, redness, swelling, pain and loss of function68 (Fig. 4). The recruited 
neutrophils possess a large arsenal of inflammatory mediators important for 
eliminating pathogens. They release granules containing proteases and 
antimicrobial polypeptides69, produce and release ROS70 and leukotrienes71 
but also secrete various cytokines, chemokines and growth factors16. 
Neutrophils are important for the later recruitment of inflammatory monocytes 
to the site of inflammation via the secretion of CCL2. The recruited monocytes 
is an important source of moDCs and inflammatory macrophages72,73.  
Neutrophils are normally short-lived cells but during inflammation they 
are exposed to growth factors that increase their life span. Factors such as G-
CSF and GM-CSF secreted by tissue macrophages enhance neutrophil 
activity and postpone neutrophil apoptosis74. However, during prolonged 
infection or chronic inflammation neutrophils will undergo apoptosis that will 
result in neutrophil ‘consumption’. If the ongoing need for neutrophils is not 
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met, normal granulopoiesis is switched to emergency granulopoiesis75. This 
state is defined by enhanced serum levels of G-CSF, enhanced myeloid 
progenitor proliferation in the BM and the release of myeloid progenitors from 
the BM to the circulation. This adaptation of the immune system can in many 
cases be crucial for the survival of the host but also increases the risk of more 
tissue damage due to cytotoxic effects of innate cell-mediated inflammation. 
 
 
Figure 4 | Definition of inflammation. The figure illustrates the 5 different elements of 
inflammation. Heat, redness, swelling, pain and loss of function.  
 
1.2.2 Innate cell migration and T cell activation 
Tissue DCs and moDCs will engulf and digest pathogens at the site of 
inflammation. These activated DCs will express CCR7 and consequently 
migrate to the secondary lymphoid organs where they present antigens to the 
T cells via the MHC class II molecule and upregulate co-stimulatory receptors 
such as CD80 and CD8676. The surrounding tissue of the inflammation, the 
type of DC but also the type of PRRs that are stimulated will instruct the DCs 
to polarize the T cells differently77. The key cytokines secreted by activated 
APCs for T cell polarization are well established78. Bacterial, viral or 
protozoan infections stimulate APCs to produce and secrete IL-12 which 
promotes interferon (IFN)-γ-producing TH1 cells79. Infections with helminth 
parasites or other macroparasites induce a different type of T cell response. 
How exactly these parasites interact with APCs and PRRs is not fully 
understood, but it has been reported that parasite antigens can interact 
directly with the mannose receptor (MR) and induce IL-4- and IL-13-producing 
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TH2 cells79,80. IL-4 itself is a central cytokine for the induction of TH2 cells, and 
granulocytes such as basophils are major producers of IL-481. Fungal and 
bacterial infections can also induce another type of TH phenotype that also 
has a pathogenic role in autoimmunity. Secretion of IL-6 and transforming 
growth factor (TGF)β drive IL-17 secretion by T cells and induces the TH17 
phenotype82,83. Additionally, it has also been demonstrated that APC 
production of IL-23 has a crucial role in the expansion and survival of TH17 
cells84. The early interaction with PAMPs and the PRRs on DCs at the site of 
inflammation are important for the later adaptive immune activation (Fig. 5).  
 
 
Figure 5 | T cell polarization by APCs. Pathogen or PRR-stimulated APCs produce 
cytokines that drive T cell polarization. IL-12 induces the TH1 phenotype, IL-4 induces TH2 
cells and the combination of IL-6 and TGFβ induces TH17 cells. 
 
 
For instance, TLR4-stimulated DCs readily activate and polarize T cells 
towards TH1 and TH17 subtypes85, whereas Dectin-1 and Dectin-2 stimulation 
specifically drive T cell activation towards the TH17 phenotype86. Conversely, 
TLR2 stimulation of DCs drives IL-4 production by TH2 cells87. A complete 
understanding of PRRs in T cell polarization by DCs is still lacking77. Other 
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myeloid cells such as neutrophils also migrate from the site of inflammation to 
the draining LN and regulate T cell activity88,89. Neutrophils are already 
evident just hours after tissue trauma in the draining LN cortex, residing close 
to follicular B cells and CD169+ subcapsular sinus (SCS) macrophages21,88. 
The exact functions of these neutrophils are not known but it has been 
reported that neutrophils can eliminate parasite-infected SCS macrophages 
and that they regulate the antigen presentation capacity of macrophages and 
DCs through myeloperoxidase90. The regulation of antigen presentation by 
neutrophils thus limits the ensuing T cell activation by the APCs. 
 
1.2.3 The role of innate cells in B cell activation 
Activated CD4+ T cells in the LNs will emigrate to the circulation via the 
inflammatory chemokine gradient, but a significant number of T cells are also 
important for local follicular B cell activation. These T cells, which are named 
follicular B helper T (TFH) cells, migrate to the B cell follicles and assist in the 
formation of germinal centers (GC)91,92. TFH cells secrete IL-21, which in turn 
provides proliferative signals to the activated B cells93.  
There are three fundamental steps for the activation of B cells: I) the 
recognition of unprocessed antigen by the BCR; II) interaction with the TCR 
and co-stimulatory receptors such as CD40L on T cells; and III) cytokine 
stimulation such as IL-6, IL-21, BAFF and a proliferation-inducing ligand  
(APRIL) for proliferation and survival of activated B cells94. The role of innate 
cells in B cell activation is already apparent during the early steps of B cell 
activation. SCS macrophages have the ability to trap draining antigens from 
the lymphatic vessels and to display them to the BCR expressed on follicular 
B cells95. Follicular dendritic cells (FDC) also present native antigens on their 
surfaces to B cells. These antigens have usually diffused into the LN and 
been retained on the FDCs via crystallizable fragment (Fc) receptors or 
complement96. FDCs also support B cell survival and proliferation through the 
production of BAFF97.  
Another important source of BAFF are neutrophils, studies in both mice 
and humans have shown that G-CSF-stimulated neutrophils from blood and 
spleen have the capacity to produce large amounts of BAFF following CXCL2 
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or lipopolysaccharide (LPS) stimulation98,99. These splenic neutrophils have 
been termed ‘B helper’ neutrophils for their dedicated role in B cell 
activation23. Importantly, B helper neutrophils only activate the innate-like 
marginal zone B cells in the spleen. Furthermore, it is evident that a large 
number of neutrophils infiltrate the LN several days later than the initial 
neutrophil infiltration wave post-immunization22. The reported function of 
these late wave neutrophils is to regulate the magnitude of T cell activation, 
but it was also noted that these neutrophils localize close to activated B cells 
and plasma cells.  
Monocytes and DCs also play a crucial role in proliferation and survival 
of activated follicular B cells. Activated CD11c+CD8α- DCs in the lymph node 
paracortex secrete high amounts of IL-6, whereas F4/80+Ly6Chi inflammatory 
monocytes entering the medulla from the circulation secrete APRIL which is 
important for plasma cell survival100. These different innate immune cells build 
up a gradient of stimulations for the activated follicular B cells as they leave 
the GC for the medulla (Fig. 6). The differentiation from an activated B cell 
towards an antibody-secreting plasma cell occurs during this journey.  
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Figure 6 | Innate immune cells regulating of B cell activation in the LNs. Innate immune 
cells regulate B cell activation in many different aspects. SCS macrophages have the ability 
to capture antigens from the lymphatic vessels and display them to the naïve follicular B cells 
in the cortex. Neutrophils migrate quickly to the cortex of the LN during inflammation and it 
has been reported that neutrophils have the ability to eliminate SCS macrophages. One could 
speculate whether this phenomenon can also regulate antigen presentation of these 
macrophages. BCR-stimulated B cells form GC with the help of TFH cells that express CD40L 
and IL-21. Activated B cells will migrate from the GC towards the medulla where they will 
pass a gradient of BAFF and IL-6 secreted from neutrophils and DCs, respectively. In the 
medulla, monocytes provide the cytokine APRIL to plasma cells that enhance their 
survivability and antibody production. 
 
1.2.4 Macrophage activation 
Macrophages are important in the initiation, effector and resolution phases of 
inflammation. They have the ability to communicate with a multitude of cells 
and have remarkable plasticity that allows them to effectively respond to 
different environmental signals. Historically, macrophages were believed to be 
activated by a combination of two cytokines secreted by activated T cells or 
NK cells, IFN-γ and TNF101. Such activated macrophages secrete high levels 
of pro-inflammatory cytokines such as IL-1, IL-6 and IL-12, and have 
enhanced microbicidal properties due to the production of radicals from the 
enzyme inducible nitric oxide synthases (iNOS) or nicotinamide adenine 
dinucleotide phosphate H oxidase 2 (NOX2)102. These macrophages were 
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named classically activated macrophages or M1 macrophages as they work in 
synergy with IFN-γ producing TH1 cells. It was later shown that M1 
macrophages also have the ability to support the differentiation of TH17 cells 
as they can produce IL-23103. It is also known today that several PRRs 
steadily activate the M1 phenotype of macrophages by inducing TNF and 
IFNβ secretion, which in an autocrine fashion further stimulates the 
macrophages104. M1 macrophages are important effector cells during 
inflammation and have the ability to reactivate antigen-specific T cells at the 
site of inflammation. They also have a pathogenic role in disease states such 
as autoimmunity35.  
In contrast to M1 macrophages, alternatively activated macrophages or 
M2/M2a macrophages are induced by IL-4 and/or IL-13105,106. The name is 
derived from the specific upregulation of the mannose receptor, CD206, but 
also via the link to the TH2 cytokine IL-4. These M2 macrophages are 
associated with wound-healing as they have high arginase expression which 
allows them to convert arginine to ornithine, a precursor for collagen and 
polyamines which are important building blocks for the extracellular 
matrix4,107. M2 macrophages also secrete chemokines such as CCL17 and 
CCL22108, which attract IL-4-producing TH2 cells that will enhance the M2 
phenotype. They also secrete growth factors that enhance stromal cell and 
endothelial angiogenesis. These properties have made cancer cells evolve to 
induce macrophages towards the M2 phenotype which in turn support tumor 
growth and survival46,109. M2 macrophages are associated with parasite 
immunity, such as nematode and helminth infections, but the mechanisms of 
parasite elimination are still not very well understood110. Another described 
M2-like phenotype of macrophages is regulatory macrophages, also known as 
M2c or M2r macrophages. They are also termed deactivated macrophages 
(dM) in some circumstances due to their inability to produce pro-inflammatory 
cytokines such as IL-6 and IL-12, as well as having a lower expression of co-
stimulatory molecules such as CD80 and CD86101,111,112. Regulatory 
macrophages can be induced by IL-10, TGFβ or glucocorticoids secreted by 
stromal cells or regulatory T cells (Treg)113. Interestingly, it has also been 
shown that regulatory macrophages can induce Tregs by secreting IL-10 and 
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TGFβ themselves114. Regulatory macrophages have the ability to suppress 
both CD4 and CD8 T cell proliferation in an IL-10- and TGFβ-dependent 
manner114-116. Furthermore, regulatory macrophages and M2 macrophages 
can also downregulate CD80 and CD86 expression on M1 macrophages (Fig. 
7).  
 
Figure 7 | M2 macrophages can suppress M1 macrophage activation. Downregulation of 
CD86 on M1 macrophages when they are co-cultured with M2-conditioned medium. 
 
Macrophages need two signals before they obtain a full regulatory phenotype. 
The first signal, such as the anti-inflammatory cytokine IL-10 has low 
stimulatory function by itself, but combined with a secondary signal such as a 
TLR stimulation, induces a prominent regulatory phenotype indicated by high 
IL-10 secretion117. In addition, pro-inflammatory cytokine production such as 
IL-12 and IL-23 is downregulated. Many of these findings are based on data 
collected from in vitro experiments based on murine BM- and peritoneal-
derived macrophages. These exemplified activation phenotypes are extremes 
in a large spectrum of macrophage activation, more recent data have 
revealed that macrophages in tissues have the ability to express both M1 and 
M2 markers at the same time, and unorthodox stimulations inducing novel 
activation pathways, indicating broad macrophage plasticity101,118.  
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Table 3 | Macrophage activation phenotypes. 
 
 
1.2.5 TGFβ – an important cytokine for the resolution of inflammation 
Resolution of inflammation is a crucial phase for limiting tissue damage and 
initiating the healing process. One key process is limiting leukocyte 
infiltration119, changes in the composition of lipid mediators and chemokines 
have an important role in limiting neutrophil recruitment and infiltration120,121. 
Neutrophils in the tissue will undergo apoptosis, this process involves the 
presentation of ‘eat me’ signals, such as phosphatidylserine, on the surface of 
the apoptotic neutrophils. Tissue macrophages recognize this signal, which 
will duly promote phagocytosis and induce an M2 or regulatory macrophage 
phenotype122-124. These macrophages will not produce pro-inflammatory 
cytokines such as TNF, IL-12 or IL-23, but instead produce and secrete anti-
inflammatory cytokines such as IL-10 and TGFβ. TGFβ has many functions 
during resolution, enhancing the repair functions of fibroblasts and endothelial 
cells but also having an overall anti-inflammatory action on many 
leukocytes125. The important role of TGFβ in immunosuppression was 
discovered when mice deficient in TGFβ were generated. These mice 
developed multiorgan inflammation and died at 3-4 weeks of age126.  
There are three isoforms of TGFβ in mammals, TGFβ1, TGFβ2 and 
TGFβ3. TGFβ1 is the predominant isoform in the immune system and it will 
be denoted TGFβ from now on in this thesis. TGFβ signaling occurs via the 
TGFβ receptor complex125,127 which is composed of two receptors, TGFβR1 
and TGFβR2. TGFβ binds to TGFβR2 which then forms a copmlex with and 
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phosphorylates the cytoplasmic tail of TGFβR1. TGFβ is a potent suppressor 
of both TH1 and TH2 differentiation, it inhibits the production of their respective 
transcription factors, T-bet and GATA2128,129. TGFβ is also a key cytokine for 
Treg induction by activating the transcription factor FoxP3. There are two 
major populations of Tregs, the inducible Tregs which are generated in the 
periphery, and the naturally occurring Tregs which develop in the thymus 
early in life130. However, TGFβ also has an important role in the differentiation 
of pro-inflammatory TH17 effector T cells. How exactly TGFβ can induce such 
functionally diverse effector T cells is not very well understood. It has been 
reported that high concentrations of TGFβ favor Treg induction by blocking IL-
23 receptor expression and enhancing FoxP3 expression, whereas low 
concentrations of TGFβ in combination with IL-6 upregulate the IL-23 receptor 
and the TH17 transcription factor RORγt131.  
TGFβ also has important immunomodulatory effects on innate immune 
cells, inhibiting the maturation of DCs by limiting the expression of MHC class 
II, CD80 and CD86132. In addition, TGFβ deactivates macrophage production 
of TNF, and in combination with IL-10 less nitric oxide (NO) is produced114,133. 
It has also been reported that TGFβ has a potent inhibitory effect on IL-12 
production in macrophages and DCs in vitro134. TGFβ is thus a pleiotropic 
cytokine with different functions on immune cells. The immunomodulatory 
functions of TGFβ are both dependent on time, location and cell type during 
inflammation, which makes TGFβ biology complex and challenging to study. 
 
1.3 Autoimmunity 
A fundamental feature of the immune system is to not recognize and react to 
self-antigens. Autoimmunity is the failure of the immune system to control and 
regulate self antigen-induced inflammation. There are more than 70 distinct 
autoimmune diseases affecting 3-5% of the total global population135. 
Autoimmunity can be organ-specific, for example the pancreas is attacked in 
Type 1 Diabetes (T1D), and the central nervous system (CNS) is affected in 
Multiple Sclerosis (MS). Autoimmunity can also be systemic such as in 
Systemic Lupus Erthyematosus (SLE) in which many different organs such as 
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the skin, joints, kidney, lungs and other tissues are attacked. Why some 
people develop autoimmunity is still not well understood, but a combination of 
environmental and genetic factors has an important role in many autoimmune 
diseases135. Most autoimmune reactions are antigen-specific and can involve 
many self-antigens for one specific disease. However, healthy people also 
have self-specific B and T cells but most people never develop autoimmune 
disease136,137. This phenomenon first and foremost indicates that central 
immune tolerance is not fail-safe and that self-reactive lymphocytes can 
escape negative selection in the thymus and BM. It also signifies that 
peripheral tolerance have an important role as a reserve system for regulating 
and controlling self-reactive lymphocytes in healthy people138. 
There are three postulated models for peripheral tolerance, (I) 
induction of anergy, (II) clonal deletion and (III) immune suppression. If a self-
reactive lymphocyte recognizes its specific antigen in the absence of co-
stimulatory signals, for instance from an immature DC or a deactivated 
macrophage, the lymphocyte will become anergic or in a state of 
unresponsiveness139,140. In some circumstances, in the absence of both co-
stimulatory signals and survival factors, the self-reactive lymphocyte can 
undergo activation-induced cell death or clonal deletion141,142. A third way of 
ensuring peripheral tolerance is through immunosuppression by Tregs and 
other regulatory innate immune cells via cellular interactions and cytokine 
secretion143,144.  
 
1.3.1 Type 1 Diabetes 
T1D is an autoimmune disease in which the insulin-producing β-cells in the 
pancreas are attacked and eliminated by the immune system145.  Insulin has a 
key function in the regulation of the blood glucose levels and deficiency in 
insulin leads to hyperglycemia. Symptoms of untreated T1D patients include 
polyuria, polydipsia, fatigue, and in severe conditions ketoacidosis and coma. 
Since β-cells do not regenerate, patients with T1D require a life-long daily 
treatment of exogenous insulin. 
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1.3.1.1 The non-obese diabetic mouse and pathogenesis of T1D 
It has always been difficult to study the immunopathogensis of human T1D 
due to the relative inaccessibility of the human pancreas. Animal models have 
thus been crucial in studying and understanding the pathogenesis of T1D. 
The non-obese diabetic (NOD) mouse strain was originally generated more 
than 30 years ago and has been fundamental to this end146. NOD mice are 
one of the most used animal models for T1D, as it clinically resembles human 
T1D in many ways. NOD mice display hyperglycemia and can be treated with 
insulin. They also have circulating autoantibodies prior to clinical 
manifestation147. However, there are other aspects of the NOD mouse model 
that do not resemble the human counterpart. First of all, these mice are highly 
inbred so they must be viewed as a single case study in humans. The onset 
of diabetes in NOD mice is around 12-15 weeks of age, an age when the mice 
can reproduce, whereas in humans most T1D cases are diagnosed during 
childhood or puberty148.  
The progression of T1D in NOD mice initiates with the accumulation of 
CD4+ and CD8+ at the pancreatic islets around 3-4 weeks of age, a process 
termed insulitis. Over the next 4-8 weeks the insulitis progressively increases 
with heightened T cell activity but also the recruitment of other leukocytes. 
Interestingly, the β-cells are not attacked during this time period149. The 
factors which trigger the immune cells to attack the β-cells are not very well 
understood, but events that may underlie this transition could be the 
acquisition of new immune effector functions, loss of sensitivity to negative 
signals, new self-antigens or the recruitment of accessory cell types150. 
However, it is well established that development of T1D in NOD mice is 
dependent on both CD4+ and CD8+ T cells151. CD4+ T cells produce 
inflammatory cytokines such as IFN-γ that upregulate the FAS receptor on β-
cells and also activate innate immune cells such as macrophages. 
Autoreactive CD8+ T cells can eliminate β-cells by MHC class I-mediated 
cytotoxicity via perforin- or the FAS-dependent pathway. T cells also have a 
role in preventing onset of T1D. NOD mice lacking Tregs develop an 
accelerated disease onset and humans with IPEX (immunodysregulation, 
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polyendocrinopathy, enteropathy, X-linked) syndrome, with mutations in the 
FoxP3 gene, can spontaneously develop T1D152,153. 
 
1.3.1.2 The role of macrophages in T1D 
Many studies in NOD mice and humans have highlighted the role of 
pathogenic T cells for the development of T1D. However, early studies have 
also shown the important role of M1 macrophages in pathogenesis of the 
disease. Inhibition of macrophage influx into the pancreas inhibits 
development of T1D154. Remarkably, M1 macrophages have been detected in 
the pancreas before lymphocyte infiltration and also in NOD/scid (severe 
combined immunodeficiency) that lack both T and B cells155. It has also been 
demonstrated that M1 macrophages have a key role in the activation of 
cytotoxic CD8+ T cells156. M1 macrophages can produce pro-inflammatory 
cytokines such as IL-1β and TNF that can stress and induce apoptosis in β-
cells155,157. Macrophages from NOD mice and T1D patients are also more 
prone to being M1 activated than are macrophages from healthy controls. 
NOD macrophages have an abnormal ratio of TNF:IL-10 production in relation 
to other mouse strains158, and macrophages from T1D patients are 
hypersensitive to LPS stimulation159. It has also been speculated that there 
are defects in the transition from M1 to M2 macrophages in the pancreata of 
NOD mice. Interestingly, there is an approximate 80% incidence of T1D in 
female NOD mice and it was recently reported that transgenic NOD mice that 
did not spontaneously develop T1D expressed M2–associated genes in the 
pancreas160. These protected NOD mice that do not develop T1D possess 
regulatory macrophages with a phagocytic/immunosuppressive phenotype161. 
 
1.3.2 Multiple Sclerosis 
MS is an autoimmune disease of the CNS and was already described in the 
mid 19th century162. The immune system attacks the proteins of the myelin 
sheath and causes demyelination in the CNS. The myelin sheath isolates the 
axons of neurons and damage to this isolation results in weakening of the 
axonal signal transmission. MS patients display oligoclonal bands in the 
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cerebrospinal fluid (CSF), lesions on magnetic resonance imaging (MRI) and 
bouts of neurological symptoms163. MS patients develop symptoms such as 
disturbances in vision, sensation, motor function or autonomic problems, 
which all depend on the location of demyelinated plaques in the CNS164. The 
disease can also be classified into sub-types: relapsing-remitting MS (RRMS), 
primary progressive MS (PPMS), secondary progressive MS (SPMS) and 
progressive relapsing MS. The majority of the patients acquire the RRMS 
form of the disease but later progress into the SPMS sub-type. The effective 
treatments today target important immune functions and modulate immune 
mediators165. However, there is still today no treatment for the progressive 
forms of MS. 
 
1.3.2.1 Experimental Autoimmune Encephalomyelitis 
The animal model for MS is termed Experimental Autoimmune 
Encephalomyelitis (EAE) and can be induced in a number of species such as 
mice, rats, rabbits and monkeys. The animal model has been used for more 
than 80 years and it has become clear that EAE can reproduce many of the 
conserved immunological aspects of MS166. However, one should appreciate 
that EAE is a model of induced neuroinflammation in inbred animals and not a 
phenocopy of the heterogeneous human disease. EAE in mice can be actively 
induced by the injection of a myelin protein together with adjuvant. The 
adjuvant frequently used is complete Freund’s adjuvant (CFA), which is 
mineral oil together with heat-killed Mycobacterium tuberculosis167. The use of 
pertussis toxin is also necessary for several mouse models. The adjuvant will 
stimulate PPRs on APCs, these innate cells will be activated and migrate to 
the draining LNs and present myelin antigen to the T cells. These activated T 
cells will then leave the LN to the circulation and migrate to the CNS168.  
It was established in the 1980s that T cells have a fundamental role in 
the induction of EAE. At that time the technique to obtain and culture myelin-
specific T cells was developed, and Ben-Nun et al adoptively transferred 
myelin basic protein (MBP)-specific T cells into naïve rats which later 
developed EAE169. Initial findings of IFN-γ expression in the CNS led to the 
hypothesis that TH1 cells were the driving force underlying inflammation in the 
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CNS. Paradoxically, mice deficient in the genes for either IFN-γ or IL-12 were 
not resistant to EAE170-172. This led to the finding of the important role of IL-23 
and TH17 cells and their pathogenic role in EAE84,173. Additionally, GM-CSF 
was recently reported to be a key pathogenic cytokine produced by TH17 cells 
in EAE174. It has also been reported that autoreactive T cells derived from the 
inflamed CNS co-express IFN-γ and IL-17175. However, MS patients who 
received IFN-γ therapeutically experienced exacerbations during this 
treatment176. Furthermore, conflicting data have been reported regarding the 
role of T-bet, the major transcription factor for TH1 cells in EAE, based on 
mice deficient for this gene177,178. 
 
1.3.2.2 The role of innate cells in EAE 
Myelin-specific CD4+ T cells are one of the first leukocytes to enter the CNS 
during adjuvant-induced EAE. These autoreactive T cells are reactivated by 
CNS-resident APCs. Microglia have been considered as poor APCs due to 
their low levels of MHC class II expression, but their importance for EAE is still 
significant as they can produce inflammatory cytokines and chemokines 
179,180. It has also been reported that CD40 expression on activated microglia 
is important for their interaction with T cells181. Perivascular (PV) 
macrophages express MHC class II and other co-stimulatory receptors such 
as CD80, CD86 and CD40182. These receptors are highly upregulated on PV 
macrophages during EAE and have been suggested to be important for the 
initial reactivation of autoreactive T cells183. These reactivated T cells will 
secrete factors important for opening of the blood brain barrier184, and the 
production of IFN-γ and TNF activates PV macrophages and microglia 
towards an M1-like phenotype182. Activated PV macrophages, microglia and T 
cells will secrete chemokines important for leukocyte recruitment and 
importantly monocytes via CCL2185. Infiltrating monocytes are an important 
source of M1 macrophages and moDCs. EAE severity correlates with the 
number of infiltrating monocytes and inhibition of this infiltration protects mice 
from EAE186,187. It has also been postulated that M1 macrophages are the key 
effector cells in demyelination whereas microglia are important for scavenging 
cellular debris during EAE188. The exact mechanisms of demyelination are not 
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known but M1 macrophages in the CNS produce ROS that could lead to 
destruction of myelin189,190.   
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2 Aims of the thesis 
 
The aim of this thesis was to understand how modulation of innate immune 
cells could regulate adaptive immune responses during inflammation and 
autoimmunity.  
 
The specific scientific goals for each study were: 
 
Study I: to assess if regulatory M2 macrophages can be induced in NOD 
mice and to test the hypothesis that regulatory macrophages 
can suppress type 1 diabetes. 
 
Study II: to investigate if microglia and macrophages can obtain a 
regulatory M2 phenotype and suppress EAE. 
 
Study III: to understand the role of TGFβ in phagocytes and the 
subsequent TGFβ-dependent effects on adaptive immunity 
during EAE. 
 
Study IV: to examine the role of neutrophils in regulating lymph node T 
and B cells after adjuvant-induced chronic inflammation. 
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3 Methods 
I have used a variety of materials and methods in this thesis, all of which are 
described in the included studies. I would like to take the opportunity to review 
some of the specific methodologies in this section.  
 
3.1 Animal models 
We have been using mice in study I, II, III and IV for many reasons. First of 
all, there is a better availability for molecular tools such as antibodies, 
cytokines and growth factors for mice than there is for other murine strains 
such as rats and guinea pigs. Many standard operating procedures for assays 
and inflammatory models have been developed and described for mice. 
Additionally, numerous inbred and congenic strains are available for different 
purposes and a variety of genetically modified mice have been developed to 
specially study certain genes and cells.  
We have been using two different mouse strains for EAE, C57BL/6 (B6) 
mice in study III (B6) and DBA/1 mice in study II. Both are dependent on 
CFA as adjuvant, while pertussis toxin is only necessary for EAE in B6 mice 
but not needed in DBA/1 mice. The majority of the gene-modified mice is on 
the B6-background or backcrossed onto the B6 background.  
 We have also used the Cre-Lox recombination technology to 
specifically delete or insert genes in specific cell types191. The technique is 
derived from bacteriophages and is based on the enzyme Cre recombinase, 
which can recombine a target sequence that is flanked by LoxP sequences. 
We have used mice expressing Cre under the Lyz2 (LyzM)-promoter in study 
III and IV. In study III we deleted exon 3 in the TGFβ receptor (Tgfbr2) 
specifically in LysM-expressing phagocytes. In study IV we introduced the 
toxin DTA in LysM-expressing cells by activating Rosa26-driven expression of 
DTA in phagocytes. The Rosa26 cassette has a stop element that is flanked 
by LoxP. The Cre recombinase will remove the stop element which will lead to 
DTA expression under the constitutively expressed Rosa26 promoter, but only 
in LysM-expressing cells.  
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3.2 Bone marrow-derived macrophages and DCs 
Analysis of macrophages and DCs was performed in study I, II and III. BM-
derived macrophages were generated by the dissection of the femurs and the 
culture of RBC-lysed BM with either 20 ng/ml of mouse M-CSF or with 20% 
L929-conditioned complete medium. The conditioned medium was exchanged 
2 times with 2-3 days interval. Harvesting of macrophages was performed 
using 0.5% Trypsin for 10 minutes at 37°C or with 0.5mM 
ethylenediaminetetraacetic acid (EDTA) for 30-45 minutes at 37°C.  
BM-derived DCs were generated in a similar fashion to BM-derived 
macrophages, but instead 20 ng/ml GM-CSF was applied.  
 
3.3 Suppression assay 
To address the immunosuppressive capacity of M2 macrophages in study I 
and II we developed a co-culture assay in which we measured regulation of T 
cell proliferation by macrophages. We coated 96-well plates with 0.3 or 0.5 
µg/ml of anti-CD3 antibody for 1-2 hours at 37°C. In some circumstance 0.5 
µg/ml of anti-CD28 antibody was added to the splenocyte solution but not 
coated. Macrophages was later harvested in the antibody-coated wells and 
stimulated for 24 hours. Macrophages were thoroughly washed with pre-
heated PBS and splenocytes or lymphocytes were subsequently added to the 
macrophages and cultured for 72 hours. Optimization experiments indicated 
that a macrophage:splenocyte ratio of 1:16 was optimal for sufficient T cell 
survival. 
 
3.4 In vivo cell tracking  
We wanted to track the migration of macrophages in study I and thereby 
used the IVIS spectrum in vivo imaging system. This system takes advantage 
of bioluminescent or fluorescent reporters in the blue or near-infrared 
wavelengths. The system is also built up of different filters that assist in the 
reduction of autofluorescence from skin and other organs.  We used the lipid 
membrane-dye DiR (1,1’-dioctadecyl-3,3,3’,3’-tetramethylindotricarbocyanine 
iodide) to stain our cells which emits light in the near-infrared spectrum upon 
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excitation. The staining of macrophages was performed with 3.5 µg/ml of DiR 
at 37°C for 5 minutes. The cells were carefully washed with an excess of ice-
cold PBS. The fluorescently labeled macrophages were injected i.p before 
imaging. Mice were anesthetized and the ventral fur was shaved to minimize 
light interference. The anesthetized mice were imaged in the IVIS spectrum 
system with excitation and emission filters set at 710 and 760, respectively.    
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4 Results and Discussion 
The studies in this Ph.D thesis were developed in order to understand the role 
of innate cells in the regulation of adaptive immune responses. I wanted to 
understand how innate immune cells such as macrophages, DCs and 
neutrophils communicate and interact with T and B cells in the context of 
inflammation and autoimmunity. 
4.1 Study I: M2 macrophages in T1D. 
 
Background   
T1D is an autoimmune disease in which leukocytes progressively eliminate the insulin-
producing β-cells in the pancreas, leading to the loss of glucose regulation.  
 
Hypothesis   
The destruction of β-cells in the pancreas is due to the pro-inflammatory environment 
induced by self-reactive T cells and M1 macrophages. We hypothesized that regulatory 
M2 macrophages should be able to regulate and reduce the activity of these pro-
inflammatory leukocytes and thus reduce the loss of β-cells and T1D development in 
NOD mice. 
 
Methods   
A protocol for induction of anti-inflammatory M2 BM-derived macrophages was devised 
involving surface and functional immunophenotyping. The stability of these M2 
macrophages was assessed by sequential stimulations. Stable M2 macrophages were 
adoptively transferred into NOD mice prior to clinical onset and the effect of therapy on 
the clinical course based on glucose levels was assessed. The fate of transferred cells 
was analyzed by live in vivo imaging and by immunohistochemistry. The effects on the 
cells in the pancreas were assessed by optical projection tomography (OPT) and 
immunological analysis of local T cell populations. 
 
Results   
IL-4/IL-10/TGFβ-treated BM-derived macrophages (M2r) were induced into a relatively 
stable regulatory phenotype based on their ability to produce IL-10 and TGFβ, to 
suppress T cell activation and their inability to produce pro-inflammatory cytokines. A 
single adoptive transfer of the M2r macrophages significantly protected >80% of the 
NOD mice from developing T1D and they remained protected for 3 months post-
transfer. OPT and immunohistochemical analyses revealed increased numbers of β-cell 
islands. In vivo imaging revealed that the transferred M2r macrophages homed to the 
pancreas within 24 hours. 
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4.1.1 The source of macrophages 
BM-derived macrophages have been a popular source to obtain large 
amounts of macrophages for in vitro studies. The BM contains both 
monocytes and GMPs that will respond to M-CSF stimulation and differentiate 
into macrophages. One can either use purified recombinant mouse M-CSF or 
M-CSF-conditioned media from the fibroblastic L929 cell line which produces 
large amounts of M-CSF192,193. The use of conditioned-media from L929 
generates a large amount of macrophages without any obvious artifacts, but 
one could still consider if these macrophages should be termed ‘L929-
differentiated’ macrophages as L929 cells produce many other factors. 
Another source of macrophages is the peritoneum. Peritoneal macrophages 
(PM) have been widely used since the 1960s, maybe due to the easy and 
quick access to mature macrophages. However, there is a big difference 
between BM-derived macrophages and mature PMs. PMs are larger than BM-
derived macrophages and PMs also have higher expression of MHC class II 
and programmed death-ligand (PD-L)1 during steady-state, as well as higher 
IL-12 and iNOS expression after activation, indicating a more mature and 
specified phenotype in PMs relative to BM-derived macrophages194. The 
macrophage yield is also different, you can retrieve approximately 3-5 million 
macrophages from the peritoneum in contrast with 10-15 million macrophages 
from two mouse femurs. We used the BM as our source of macrophages as 
we wanted large numbers of macrophages that were as naïve as possible for 
different manipulations we systemically wanted to address.   
  
4.1.2 The induction and stability of M2r macrophages 
To determine the optimal M2 activation protocol we needed to evaluate 
different stimuli. We chose IL-4, IL-10, IL-13, TGFβ, dexamethasone and 
vitamin D for M2 induction based on previous knowledge46. We also 
combined IL-4, IL-10 and TGFβ to determine if there were any synergistic 
effects of these cytokines. IL-10, TGFβ and dexamethasone had a very potent 
effect in the downregulation of IL-6 secretion in M1 macrophages, whereas 
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TGFβ alone significantly upregulated IL-10 and TGFβ secretion (Fig. 8A). IL-4 
enhanced the phagocytic capacity of macrophages and the expression of PD-
L2. Interestingly, PD-L2 expression was further increased when IL-4 and IL-10 
was combined. We also detected synergistic effects with IL-10 and TGFβ in 
the suppression of NO secretion and the expression of the anti-inflammatory 
B7-H4 receptor (Fig. 8B). These results indicate that a combination of IL-4, IL-
10 and TGFβ could induce a macrophage phenotype (M2r) that included 
regulatory and wound-healing properties based on secretion of anti-
inflammatory cytokines, the expression of specific receptors and their higher 
phagocytic capacity. We believed that these two distinct but combined 
phenotypes would be optimal for the environment in the pancreas to increase 
β-cell survival and suppress inflammatory responses.  
 
 
Figure 8 | IL-4, IL-10 and TGFβ  induces a unique M2 phenotype. (A) Macrophages were 
stimulated with the respective stimuli and different cytokines were measured. (B) NO 
secretion and PD-L2 expression induced by different stimuli. 
 
It is also known that macrophages are very plastic and can quickly 
adapt and change their phenotype. We therefore addressed the question if 
these M2r macrophage would retain their properties upon secondary pro-
inflammatory stimuli. We thus first skewed naïve macrophages into M2r 
FIG. 1. IL-4, IL-10, and TGF-b induce a distinct anti-inﬂammatory M2 phenotype. Macrophages (13 105) were costimulated for 72 h with the respective
stimulus and LPS/IFN-g to determine levels of the proinﬂammatory mediators NO (A) and IL-6 (B). C: TNF measurement after activation with the
respective stimulus for 24 h followed by secondary stimulation with LPS/IFN-g for 24 h (48 h). D: Endocytosis assessed by stimulating 5 3 105 mac-
rophages for 24 h with the respective stimulus followed by 4 h incubation with Alexa Fluor 647–coupled dextran. Bars represent mean ﬂuorescence
intensity (MFI). E: Levels of biologically active TGF-b secretion in 5 3 105 macrophages stimulated for 1 h, followed by 24 h incubation in fresh
complete medium. F: IL-10 after costimulation of 5 3 105 macrophages for 1 h with the described stimulus and LPS, and further incubation in fresh
complete medium for 24 h. G: Gene expression of costimulatory molecules identiﬁed using low-density arrays. Color patterns visualize fold gene ex-
pression relative to untreated controls (red indicates increase, green indicates decrease, and black designates no fold difference). H: PD-L1, PD-L2, and
CD86 receptor expressions analyzed by ﬂow cytometry (MFI) using receptor-speciﬁc antibody staining. Each color represents one macrophage stim-
ulation (24 h) regimen. All results are representative of three independent experiments. Statistical comparisons were conducted against LPS/IFN-g
(A and B) or untreated (C–H) controls (black bars; n = 4). White bars represent negative controls. ND, not detectable. Error bars are presented in SEM.
*P < 0.05.
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macrophages and subsequently stimulated them with LPS/IFN-γ. The M2r 
macrophages did not obtain a strong M1 phenotype (based on their limited 
TNF secretion) in contrast to M1 stimulated macrophages, indicating a 
relatively stable M2r phenotype. Furthermore, we analyzed M1 and M2-
associated genes by PCR to obtain a more detailed overview of their 
phenotype. We detected upregulation of M1-associated genes such as PD-
L1, Nos2 and Cd86, yet the M2-associated genes such as Arg1, Tgfb1 and 
PD-L2 were still expressed. These results indicate that macrophages do 
respond to new stimuli and adapt to the new environment, but they do 
‘remember’ their earlier phenotype. Importantly, the results were also 
confirmed in vivo using fluorescently-labeled M2r macrophages that had been 
transferred into NOD mice and then recovered from the pancreas.  
 
4.1.3 M2r macrophages suppress T cell proliferation and induce Tregs 
We wanted to evaluate the potential regulation of T cells by M2r macrophages 
as the pathogenesis of T1D is driven by self-reactive CD4+ and CD8+ T cells 
in the pancreas. To address this we developed an in vitro suppression assay 
by co-culturing M2 macrophages and anti-CD3-stimulated splenic T cells. The 
co-cultures revealed that TGFβ stimulation is crucial for the ability of M2 
macrophages to suppress T cell proliferation. The suppression of T cells 
occurred via secreted factors or via a cell contact-dependent mechanism 
based on a transwell system and fixation of the macrophages, respectively. 
Furthermore, IL-10 and TGFβ had a synergistic effect on macrophages in the 
differentiation of inducible Tregs based on FoxP3 expression.  
It has been speculated whether M-CSF-dependent resident tissue-
macrophages have intrinsic immunosuppressive and M2-like properties as a 
homeostatic function in order to protect the local tissue195,196. For instance, M-
CSF-generated macrophages produce and secrete more IL-10 in contrast to 
GM-CSF-generated macrophages. M-CSF has the ability to enhance the 
expression of M2-assoaciated genes both in mice and Man. Additionally, it 
has been reported that M-CSF signaling in BM myeloid precursors from NOD 
mice is dysregulated197. 
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4.1.4 M2r macrophages prevent mice from developing T1D 
The accumulated data for M2r macrophages indicates that these cells have 
enhanced phagocytic capacity, inability to produce pro-inflammatory cytokines 
but instead secrete anti-inflammatory cytokines, and have the capacity to 
suppress T cell proliferation and induce Tregs. We therefore wanted to 
understand the role of these M2 macrophages in T1D, but also to investigate 
if M2r macrophages could be used therapeutically for treating T1D in NOD 
mice. Adoptive cell transfer has been utilized before in NOD mice with the use 
of Tregs or tolerogenic DCs198,199. The main issue with Tregs is their antigen-
specificity - in mice this is a controllable parameter whereas in humans it is 
much more difficulty to predict the active antigen(s)200. DCs with a tolerogenic 
phenotype indicated by low expression of co-stimulatory molecules such as 
CD80 and CD86 are usually induced by applying dexamethasone or IL-10 
and have also been employed in adoptive transfer settings. The obvious risk 
with DCs is that they are good inducers of immunity as they have the capacity 
to express high amounts of MHC class II, CD80 and CD86. The half-life of 
DCs is also relatively short, which could make them less effective in their 
ability to suppress chronic inflammation. 
 We decided to transfer M2r macrophages at the later stage of the 
disease when the insulitis activity was at the highest but mice are still without 
any clinical manifestations. We transferred 2.5 million M2r macrophages i.p 
into 16 week- old female pre-diabetic NOD mice. We also injected vehicle 
(PBS) and untreated macrophages (M0) as controls for our therapeutic 
intervention. The first mice started to develop T1D just 1 week after the 
transfer, and following the mice for 3 months revealed that M2r macrophages 
protected more than 80% of the mice from developing T1D, in contrast to the 
two control groups which both developed normal frequencies of T1D onset in 
NOD mice (Fig. 9A). Immunohistochemistry of pancreas from 24-week-old 
M2r- and M0-treated mice visualized a significant increase of insulin+ islands 
in the pancreata of M2r-treated mice (Fig. 9B).  
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Figure 9 | M2r macrophages prevent NOD mice from developing T1D. (A) 2.5 x 106 M2r, 
M0 (untreated) or vehicle (PBS) was injected i.p into 16-week old pre-diabetic NOD mice. (B) 
Insulin+ islets were counted in 24-week-old NOD mice after M0 or M2r macrophage transfer. 
 
4.1.5 In vivo tracking of transferred M2r macrophages  
To determine if the M2r macrophages migrated to the pancreas we took the 
advantage of using in vivo imaging to track the cells directly in living mice. We 
stained both M2r and M0 macrophages with the lipophilic fluorochrome DiR 
that will make the cells light up in the near-infrared range. Macrophage 
migration was already evident 2 hours post-injection and 24 hours later we 
could detect a strong signal around the area of the pancreas. Interestingly, we 
did not detect any different pattern in migration between M2r and M0 
macrophages. Dissection of the liver, kidneys, spleen, pancreas and 
pancreatic LN (pLN) confirmed that the macrophages predominantly migrated 
to the pancreas but also to the pLN. It also indicates that a core macrophage 
chemokine receptor profile is involved in their migration to these tissues. Only 
a few chemokine receptors were differentially expressed in M2r compared to 
M0 macrophages based on genome-wide expression analysis (Table 4). 
 
Table 4 | Chemokine receptors on M2r 
relative to M0 macrophages 
Gene P-value Fold 
Cxcr2 6,81E-07 3,05 
Cxcr7 0,000730423 1,89 
Cxcr4 3,12E-05 -1,64 
Cxcr3 3,29E-05 -2,04 
Ccr2 8,32E-05 -4,45 
Cx3cr1 4,25E-06 -8,99 
 
FIG. 4. M2r macrophages protect NOD mice from T1D by protecting pancreatic b-cells. A: IL-4/IL-10/TGF-b–stimulated macrophages (2.53 106) (M2r,
blue, n = 12), untreated macrophages (M0, red, n = 8), or vehicle (PBS, black, n = 8) were intraperitoneally injected into 16-week-old prediabetic NOD
mice (arrow). The M2r-treated group was signiﬁcantly protected compared with M0 and PBS groups, as independently statistically analyzed using the
Mantel-Cox test in a Kaplan-Meier survival graph. These results are representativ data from two independent experiments with a similar outcome.
B: Organs were stained with anti-insulin (red) and anti-CD3 (green)–speciﬁc antibodies prior to three-dimensional reconstruction using optical
projection tomography. Yellow represents colocalization of CD3 nd insulin staining, indicating insulitis. Organs from 16-week-old mice represent
three individual animals; 21- and 26-week-old organs represent two individual animals. C: After M2r or M0 macrophage transfer, pancreata were
dissected 8 weeks later (24 weeks of age), and cryosections were stained with anti-insulin (red) and anti-CD3 (green) (n = 5). D: Insulin+ islets were
counted manually from the sections in two to ﬁve transverse sections per animal to obtain the average number of insulin+ islets per section (n = 4). *P
< 0.05. (A high-quality digital representation of this ﬁgure is available in the online issue.)
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We next sought the answer for what these M2r macrophages were 
doing to protect the β-cells. We speculated two possible mechanisms: either 
that M2r macrophages regulated the activation or infiltration of self-reactive T 
cells, or that M2r macrophages nursed and supported β-cell survival through 
soluble factors. Immunohistochemical analysis and OPT imaging indicated no 
differences in T cell numbers. To confirm this we injected M2r or M0 
macrophages into NOD mice and analyzed the T cell compartment in the 
pancreas and the draining pLN 1 week post-transfer. Our analysis of these 
organs confirmed that there were no differences in the CD4+ and CD8+ T cell 
pools, nor did we detect any increase in FoxP3+ Tregs. These data indicate 
that M2r macrophages do not limit lymphocyte infiltration into the pancreas or 
pLNs. To address if the T cell activation or proliferation states were 
manipulated by M2r macrophages we used TCR transgenic BDC2.5 NOD 
mice in which the majority of the CD4+ T cells are specific for a β-cell antigen. 
We injected either M0 or M2r macrophages into these mice and dissected the 
pLN 1 week post-injection. The lymphocytes from the pLN were then 
restimulated with the BDC2.5 mimotope for 72 hours in order to induce 
proliferation. Interestingly, we detected a significant reduction in T cell 
proliferation from mice that received M2r macrophages. Additionally, T cells in 
M2r-treated pLN displayed a trend to be less activated based on CD62L and 
CD44 expression.  
These data indicate that M2r macrophages limit the proliferative capacity 
of T cells in the pLN and maybe also limit their activation status. However, we 
did not detect any differences in the numbers of Tregs in either the pancreas 
or the pLN. One could consider if the suppressive capacity of these Tregs is 
enhanced by M2r macrophages. Furthermore, a recent study has reported 
that M2 macrophages support β-cell proliferation in a TGFβ- and epidermal 
growth factor (EGF)-dependent manner. M2r macrophages secrete TGFβ, 
which could explain another possible therapeutic effect of M2r macrophages 
in T1D201. 
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4.2 Study II: M2 macrophages and microglia in EAE 
 
 
 
 
 
 
 
 
 
 
 
 
Background   
MS is an autoimmune disease in which macrophages attack and destroy the myelin 
sheath surrounding the neuron axons, leading to neurological disability.  
 
Hypothesis   
Adoptive transfer of pre-activated anti-inflammatory macrophages or microglia will 
efficiently down-regulate experimental MS in mice.  
 
Methods   
A protocol for the cell culture of adult microglia was established. Induction of anti-
inflammatory M2 macrophages and microglia was conducted based on a previously 
developed procedure. Immunophenotyping was performed on M2 macrophages and 
microglia, and the properties of these cells were also compared. Anti-inflammatory M2 
macrophages and microglia were adoptively transferred into DBA/1 mice at different 
timepoints during EAE. The fate of transferred cells was followed by 
immunohistochemical analysis. Immunological analysis of CNS T cell populations in 
treated mice was investigated in order to determine the effect of macrophages/microglia 
on adaptive immunity. 
 
Results   
Stimulation with IL-4/IL-10/TGFβ induced M2 microglia with an immunosuppressive 
phenotype. These M2 microglia had decreased expression of CD86, PD-L1, NO and IL-
6 and increased expression of PD-L2 and IL-10. M2 microglia suppressed T cell 
proliferation and induced regulatory T cells. A single transfer of M2 microglia attenuated 
the severity of established EAE, which was most obvious when the cells were 
transferred at 15 days post-immunization. M2 microglia-treated mice had reduced 
inflammation and less demyelination in the CNS. 
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4.2.1 Macrophages and microglia in the CNS 
Microglia are considered to be the resident tissue macrophages in the CNS. 
These cells are originally derived from the yolk-sac progenitors during 
embryonic development202. In a healthy brain, microglia express low levels of 
immunomodulatory receptors such as MHC class II, CD80 and CD86. 
However, this quiescent state is still very dynamic as microglia survey the 
tissue continuously, which is important for tissue remodeling and wound 
healing203. It has been shown that acute and chronic inflammation in the CNS 
induces an M1 microglia phenotype with increased MHC class II expression 
and enhanced secretion of pro-inflammatory cytokines204. It has been debated 
if the M1 phenotype is specifically associated to microglia or if it is linked to 
monocyte-derived macrophages that resemble microglia during inflammation. 
Nonetheless, recent findings have described different roles for these two cell 
types, monocyte-derived cells being responsible for the inflammatory 
responses during EAE whereas microglia being more involved in the 
phagocytosis of cellular debris188,205. Another resident phagocyte in the 
perivascular space of the CNS is the PV macrophage. The PMs are believed 
to be derived from monocytes or monocyte progenitors during adulthood206. 
These cells have high expression of MHC class II and co-stimulatory 
molecules, and are considered to be responsible for the reactivation of 
infiltrating MOG-specific T cells in the perivascular space during EAE207,208.  
 We used both macrophages and microglia in this study to understand 
their therapeutic role in EAE. The source of macrophages was from the BM, 
similar to study I. However, microglia have traditionally been cultured and 
expanded from neonatal CNS. We have reported that neonatal and adult 
microglia have different gene expression profiles and thus could act differently 
upon stimulation209. We therefore decided to use adult microglia as our EAE 
experiments were performed in adult mice.   
 
4.2.2 Induction of M2 microglia  
To determine if microglia can obtain an immunosuppressive M2 phenotype we 
took advantage of our findings in study I. We stimulated microglia with IL-
4/IL-10/TGFβ and measured receptor expression and cytokine secretion. 
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Similar to macrophages, distinct profiles of microglia activation were 
observed. M2-stimulated microglia had increased expression of PD-L2 and IL-
10 and secreted little or no pro-inflammatory cytokines. In contrast, M1-
stimulated microglia had increased expression of CD86, PD-L1 and pro-
inflammatory mediators such as IL-6 and NO (Fig. 10A). Interestingly, 
microglia that had been stimulated with LPS sequentially had decreased 
expression of pro-inflammatory markers, this phenomenon is termed 
‘endotoxin tolerance’ and has been described as a ‘memory’ function of 
myeloid cells to limit tissue damage and enhance bacterial elimination210. To 
determine if microglia could retain their M2 phenotype we first pre-stimulated 
the cells with IL-4/IL-10/TGFβ for 24h. We then washed the cells to remove 
the M2-inducing cytokines and restimulated the cells with LPS for another 
24h. Analysis of the supernatants 48h later revealed that M2 microglia indeed 
secreted pro-inflammatory mediators, but significantly less than M1-activated 
microglia (Fig. 10B). These data suggest that microglia can obtain an M2 
phenotype similar to the M2r macrophages generated in study I.  
 
 
Figure 10 | Induction of M2 microglia. (A) Expression and secretion of PD-L2 and IL-10, 
respectively. (B) IL-6 secretion in M2-microglia after secondary stimulation of LPS. 
 
4.2.3 Adoptive transfer of M2 macrophages and microglia in EAE 
We next wanted to address the question if macrophages or microglia in an M2 
state could reduce inflammation in the CNS and attenuate EAE in DBA/1 
mice. The first question we had was the route for adoptively transferring M2 
macrophages and microglia. We injected the cells i.p in study I as that was 
anatomically the closest route for macrophages to the pancreas. However, it 
was not likely that macrophages or microglia would travel from the peritoneal 
(during chronic disease). When cytokine-induced immuno-
modulatory macrophages were injected intravenously at day
15 p.i into EAE mice, similar beneficial effects were observed
(Fig. 4).
EAE Mice Treated with M2 Microglia Have Reduced
Inflammatory Responses and Less Demyelination in
the CNS
The typical pathological changes of EAE consist of CNS
inflammatory cell infiltration, demyelination, and axonal loss
during severe disease. To assess inflammation and demyelin-
ation, CNS tissues from EAE mice were divided into 10 seg-
ments as depicted in Fig. 5A and stained with hematoxylin–
eosin, luxol fast blue, and antibodies specific for Iba1 and
GFAP, with inflammatory cell infiltration being assessed
blindly in a semiquantitative fashion. At day 30 p.i (15 days
after adoptive microglia transfer) PBS-treated mice clearly
demonstrated inflammatory infiltration, microglial and astro-
cyte activation in the brain stem, cerebellum, and the whole
spinal cord. It was also obvious that demyelination occurred
throughout the spinal cord in PBS-treated mice. Moreover,
the infiltration and demyelination were especially strong in
the lumbar spinal cord (Fig. 5C). Conversely, a lower degree
of infiltration and demyelination was detected in mice treated
with M2 microglia. The infiltration scores indicated that
transfer of M2 microglia led to significantly reduced spinal
cord destruction (Fig. 5B). Smaller infiltrates were detectable
in the forebrain of approximately half of the animals, and
FIGURE 2: Microglial stimulation with IL-4/IL-10/TGF-b induces an M2 phenotype. Cultured microglia from adult DBA/1 mice were stimu-
lated for 24 h with IFNc/LPS or IL-4/IL-10/TGFb, either alone or in combination. Expression of: CD86 (A); PD-L1 (B); PD-L2 (C); IL-6 (D);
nitric oxide (NO) (E); and IL-10 (F). Secondary IFNc/LPS proinflammatory stimulation following initial M2 stimulation: levels of IL-6 (G);
NO (H); and IL-10 (I). *P<0.05; **P<0.01; ***P<0.001. Data represent at least three independent experiments.
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cavity to the CNS. It has been described that peritoneal macrophages injected 
intravenously (i.v) are captured in the lungs and our own experiments indeed 
confirmed that BM-derived macrophages transferred by the i.v route did not 
enter the CNS211. We therefore decided to investigate if intranasal (i.n) 
administration could enhance migration of microglia to the CNS. The i.n. route 
has been widely used for the delivery of cells and molecules to the olfactory 
bulb (OB) in mice212,213. Using immunohistochemistry we could confirm that 
fluorescently labeled M2 microglia did migrate to the OB after i.n injection 
(Fig. 11A). 
 
 
Figure 11 | Adoptive transfer of M2 microglia. (A) I.n. injection of fluorescently labeled M2-
microglia (red). Analysis of the OB 24h post-transfer and staining of Iba1 (green) (B) I.n 
injection of 3 x 105 M2 microglia (left) or M2r macrophages (right) at day 15 post-
immunization. 
 
We transferred M2 microglia i.n at different time points to determine the 
effect of these cells on EAE. Transfer of M2 microglia at day 0 post-
immunization (p.i) did not affect EAE. However, transfer on day 5, 12 and 15 
p.i had a significant reduction of EAE severity at the late persistent stage of 
the disease (Fig. 11B). Similar effects were also observed when we 
transferred BM-derived M2r macrophages at day 15 post-injection. These 
data suggest that M2 microglia have an important role during the later phase 
of EAE, a period when remyelination and tissue healing is crucial. A recent 
study has reported a switch from M1 microglia into M2 microglia in a model of 
lysolecithin-induced demyelination214. These M2 microglia enhanced 
remyelination by promoting oligodendrocyte differentiation, and depletion of 
M2 microglia reduced remyelination and oligodendrocyte differentiation. 
Furthermore, depletion of M2 microglia enhanced the activity and numbers of 
although there was a trend toward less infiltration in the
br in of M2 microglia-treated mice, this did not reach stati -
tical significance.
The fate of the transferred cells is a central issue and
using fluorescent DiI labeling we were able to detect trans-
ferred microglia in the olfactory bulb 24 and 72 h after deliv-
ery (Fig. 5D). Moreover, after 72 h the microglia were also
detected in the brain-draining deep cervical lymph nodes
(Fig. 5E). At this time point we could not detect labeled cells
in the rest of the brain or spinal cord.
Adoptive Transfer of M2 Microglia Suppresses
T-Cell Activation and Th17 Production in the
CNS of EAE Mice
Given the impressive therapeutic effect of M2 microglia ther-
apy in EAE mice, CNS tissues (brain and spinal cord) from
M2 microglia- and PBS-treated mice were more closely exam-
in d for immune activities by flow cytometry on day 30 p.i
(day 15 after adoptive microglia transfer). Consistent with the
histological findings, compared with PBS-treated mice M2
microglia-treated mice had reduced macrophage/microglia
(CD11b1) and T-cell (CD31) infiltration (Fig. 6A,B). Even
though there was no difference in the percentages of CD4
and CD8 cells (Fig. 6C,D), the PBS-treated group had a
higher number of activated CD4 T cells (CD62L2,
CD44high) than the M2 microglia-treated group (Fig. 6F).
Moreover, the PBS- and M2 microglia- treated mice had sim-
ilar numbers of IFN-c1 CD4 T cells in the CNS tissues (Fig.
6G). However, fewer IL-171 CD4 T cells were evident in the
CNS tissue following M2 microglia treatment (Fig. 6H).
The Immunomodulatory Properties of M2 Microglia
Act on Both Innate and Adaptive Immune Cells
In an effort to try and further discern the observed mecha-
nism of therapeutic action of M2 microglia we assessed their
effects on different aspects of innate and adaptive immunity.
The expansion of effector T cells is important in driving
experimental autoimmune disease during both initiation and
FIGURE 4: Adoptive transfer of M2 macrophages at day 15 postimmunization (p.i) diminishes the severity of established EAE. M2 macro-
phages were injected intravenously into MOG-EAE DBA/1 mice at two time points p.i: (A) day 0 and (B) day 15. Comparison of accumu-
lative clinical scores between PBS-treated EAE mice and M2 macrophage-treated EAE mice is presented for each time point. *P<0.05.
Data represent two independent experiments.
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FIGURE 3: Adoptive transfer of M2 microglia attenuates the clinical symptoms of established EAE. M2 microglia were injected intrana-
sally into MOG-EAE DBA/1 mice at different time points postimmunization (p.i): (A) day 0; (B) day 5; (C) day 12; and (D) day 15. Compar-
ison of accumulative clinical scores between PBS-treated EAE mice and M2 microglia-treated EAE mice is presented for each time point.
*P<0.05; **P<0.01. Data represent two independent experiments.
810 Volume 62, No. 5
FIGURE 3: Adoptive transfer of M2 microglia attenuates the clinical symptoms of established EAE. M2 microglia were injected intrana-
sally into MOG-EAE DBA/1 mice at different time points postimmunization (p.i): (A) day 0; (B) day 5; (C) day 12; and (D) day 15. Compar-
ison of accumulative clinical scores between PBS-treated EAE mice and M2 microglia-treated EAE mice is presented for each time point.
*P<0.05; **P<0.01. Data represent two independent experiments.
810 Volume 62, No. 5
although there was a trend towar less infiltration in the
brain of M2 microglia-treated mice, this did not reach statis-
tical significance.
The fate of the transferred cells is a central issue and
using fluorescent DiI labeling we were able to detect trans-
ferred microglia in the olfactory bulb 24 and 72 h after deliv-
ery (Fig. 5D). Moreover, after 72 h the microglia were also
detected in the brain-draining deep cervical lymph nodes
(Fig. 5E). At this time point we could not detect labeled cells
in the rest of the brain or spinal cord.
Adoptive Transfer of M2 Microglia Suppresses
T-Cell Activation and Th17 Production in the
CNS of EAE Mice
Given the impressive therapeutic effect of M2 microglia ther-
apy in EAE mice, CNS tissues (brain and spinal cord) from
M2 microglia- and PBS-treated mice were more closely ex m-
ined for immune activities by flow cytometry on day 30 p.i
(day 15 after adoptive microglia transfer). Consistent with the
histological findings, compared with PBS-treated ice M2
microglia-treated mic had reduced macr phage/microglia
(CD11b1) and T-cell (CD31) infiltration (Fig. 6A,B). Even
though there was no difference in the percentages of CD4
and CD8 cells (Fig. 6C,D), the PBS-treated group had a
higher number of activated CD4 T cells (CD62L2,
CD44high) than the M2 microglia-treated group (Fig. 6F).
Moreover, the PBS- and M2 microglia- treated mice had sim-
ilar numbers of IFN-c1 CD4 T cells in the CNS tissues (Fig.
6G). However, fewer IL-171 CD4 T cells were evident in the
CNS tissue following M2 microglia treatment (Fig. 6H).
The Immunomodulatory Properties of M2 Microglia
Act on Both Innate and Adaptive Immune Cells
In an effort to try and further discern the observed mecha-
nism of therapeutic action of M2 microglia we assessed their
effects on different aspects of innate and adaptive immunity.
The expansion of effector T cells is important in driving
experimental autoimmune disease during both initiation and
FIGURE 4: Adoptive transfer of M2 macrophages at day 15 postimmunization (p.i) diminishes the severity of established EAE. M2 macro-
phages were injected intravenously into MOG-EAE DBA/1 mice at two time points p.i: (A) day 0 and (B) day 15. Comparison of accumu-
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FIGURE 5: EAE mice treated with M2 microglia have reduced inflammatory responses and less demyelination in the CNS at day 30 post-
immunization (day 15 after adoptive microglia transfer) as assessed by immunohistochemistry. (A) Schematic figure illustrated that CNS
tissues from EAE mice were divided into 10 segments and stained with hematoxylin–eosin, luxol fast blue, and antibodies against Iba1
and GFAP, with inflammatory cell infiltration being assessed blindly in a semiquantitative fashion, from2 (no infiltration) to 111 (severe
infiltration). (B) The infiltration scores indicated that transfer of M2 microglia led t diminished spinal cord destruc ion. (C) Represe ta-
tive slices from lumbar spinal cord showed reduced degree of inflammation and demyelination in mice treat d with M2 microglia. (D)
Fluorescent DiI-labeled microglia (red) were detected in the olfactory bulb 24 and 72 h after delivery. DiI-labeled cells were designated
as microglia by staining with Iba1 (green) and DAPI (blue). (E) DiI-positive cells were detected in the brain-draining deep cervical lymph
nodes (LN) 72 h after delivery. **P<0.01; ***P<0.001. Data represent two independent experiments.
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M1 microglia, indicating an important crosstalk between M1 and M2 microglia 
in vivo. We also observed this crosstalk in vitro when M1 macrophages and 
M2 microglia were co-cultured in different ratios and M1 markers were 
measured.  
 
4.2.4 Immunomodulation of M2 microglia in the CNS during EAE 
We next wanted to explore if M2 microglia could regulate the inflammatory 
response in the CNS during the persistent phase of EAE. 
Immunohistochemical analysis indicated a reduced infiltration of leukocytes 
and less demyelination in M2-treated mice in contrast to control mice. 
Qualitative analysis of the inflamed CNS by flow cytometry confirmed these 
findings and revealed a significant reduction of CD11b+ myeloid cells and 
CD3+ T cells. The effector phenotype of the T cells was altered, with reduced 
activation status as defined by CD62L and CD44, but also reduced IL-17 
production by the T cells following M2 microglia treatment. These findings 
were confirmed when we co-cultured M2 microglia with anti-CD3 activated T 
cells in vitro and recorded reduced T cell proliferation. Similar to M2r 
macrophages in study I, M2 microglia also induced Tregs in vitro.  
Taken together, these findings demonstrate that M2 microglia have the 
ability to reduce inflammation in the CNS either by limiting leukocyte 
infiltration or by modulating their effector functions. However, we also detect 
M2 microglia in the draining LNs, which could regulate lymphocyte emigration 
and activation. The transferred microglia were not pulsed with any antigen 
and still had an immunomodulatory effect on T cells. M2 microglia have 
enhanced phagocytosis that could lead to local uptake of debris and antigens, 
including of self-antigens.  
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4.3 Study III: The role of TGFβ in moDCs during EAE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Background   
MS is an autoimmune disease characterized by immune-mediated demyelination and 
axonal loss. TGFβ is a pleotropic cytokine with many functions in both homeostasis and 
during inflammation. The role of TGFβ-signaling in phagocytes during autoimmunity has 
been poorly defined. 
 
Hypothesis   
TGFβ signaling in phagocytes within the CNS is critical for resolution of experimental 
neuroinflammatory disease.  
 
Methods   
We crossed LysM-CRE mice with TGFbrIIflox/flox mice in order to generate a mouse 
specifically lacking the expression of TGFβRII on myeloid cells. Extensive 
immunophenotyping of both phagocytes and lymphocytes was performed in order to 
assess the role of TGFβ in monocyte-derived cells during EAE. Chimeric mice were 
generated to determine the role of TGFβ on BM-derived or CNS-resident cells during 
EAE. 
 
Results   
TGFbr2-deficiency in myeloid cells resulted in a more severe disease during the 
persistent phase of EAE, without clinical remission. TGFbr2-deficient BM-derived 
macrophages and DCs had increased IL-12 production that skewed T cells to produce 
more IFN-γ. This IFN-γ in turn enhanced the activation of CNS-infiltrating moDCs by 
increasing the release of ROS. The enhanced ROS production promoted demyelination 
and persistent disease severity in mice deficient of TGFbr2 on moDCs. 
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4.3.1 TGFβ signaling in phagocytes is important for EAE remission 
TGFβ has multiple functions during both homeostasis and inflammation. The 
activity of TGFβ is dramatically increased in the CNS during acute EAE215. 
TGFβ and its receptors have been identified in CNS lesions of human MS 
patients216. However, studies of the function of TGFβ in the CNS during EAE 
have yielded conflicting results. TGFβ can have both pro- and anti-
inflammatory functions, administration of TGFβ reduces the symptoms of EAE 
and suppress T cell proliferation217,218, similar to the in vitro findings in study I 
and II. However, in those studies TGFβ was injected systemically (s.c and i.v) 
and not directly at the site of inflammation. Paradoxically, neutralization of 
TGFβ by antibodies exacerbated EAE and pharmacological inhibition of TGFβ 
signaling resulted in earlier onset of EAE215,219. Another study reported that 
overproduction of TGFβ in the CNS worsens EAE220. Furthermore, TGFβ has 
an important role in the differentiation of both pathogenic TH17 cells and 
protective Tregs. These conflicting data could be explained by the complex 
biology of TGFβ, the net effect of this cytokine being dependent on the tissue, 
phase of inflammation and the cell that is targeted125.  
We wanted to address the effect of TGFβ on myeloid cells during EAE, 
and therefore crossed LysM-Cre with TGFβRIIflox/flox mice to generate 
TGFβRII-deficiency specifically in the myeloid compartment (LysM-TGFbR2). 
LysM is expressed in phagocytes such as macrophages, monocytes and 
neutrophils and has been widely used for phagocyte gene-targeting221. We 
immunized s.c the LysM-TGFbR2 mice and littermate controls (WT) with 
myelin oligodendrocyte glycoprotein (MOG) in CFA and determined the 
clinical outcome of EAE. There was no difference in the onset or the acute 
phase of EAE between LysM-TGFbr2 and WT mice. However, WT mice 
entered the remission phase around day 17 with reduced disease severity, 
whereas the disease severity of LysM-TGFbr2 mice was not attenuated and 
did not convert into remission throughout the period of observation (Fig. 12A). 
Similar findings have been reported when the promoter of CD11c was used to 
drive the expression of a dominant negative form of TGFβRII in the cDC 
subset222. Analysis of the persistent phase of EAE (day 24-28) by flow 
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cytometery and immunohistochemistry indicated enhanced leukocyte 
infiltration in the LysM-TGFbr2 CNS, primarily comprising activated moDCs 
and CD3+ T cells (Fig. 12B). Furthermore, LysM-TGFbr2 mice had 
considerably increased demyelination compared to WT controls at the 
persistent phase of EAE. This could either indicate enhanced inflammatory 
responses or dysfunctional remyelination.  
 
 
Figure 12 | LysM-TGFbr2 mice have severe EAE without remission with increased 
moDC infiltration to the CNS. (A) Clinical score of EAE on LysM-TGFbr2 and WT mice (B) 
Infiltrating cell types in the CNS at day 24. White bars: WT, black bars: LysM-TGFbr2 (C) 
LysM gene expression in sorted moDCs and microglia (D) Recombination of exon 4 in the 
Tgfbr2 locus in sorted moDCs and microglia (E) Recombination of exon 3 in the Tgfbr2 locus 
in sorted YFP+ monocytes from LysM-TGFbr2 / Rosa26-EYFP mice. 
 
To determine if the loss of TGFβ signaling was in blood-derived myeloid cells 
or in tissue-resident cells we first analyzed LysM expression in moDCs and 
microglia. We only detected LysM gene expression in moDCs and not in 
microglia (Fig. 12C). Furthermore, we only detected high recombination of the 
Tgfbr2 locus in moDCs (Fig. 12D). Additionally, we crossed LysM-TGFbr2 
mice with Rosa26-stopflox-EYFP mice to be able to sort out monocytes and 
analyze recombination of the Tgfbr2 locus in those cells. Splenic YFP+ 
monocytes, similar to moDCs in the CNS, had recombination of the Tgfbr2 
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locus, indicating that TGFβRII-deficiency already appears at the monocyte 
stage (Fig. 12E).  
Analysis of the draining inguinal LNs (iLN) at day 7 and the CNS at the 
acute phase (day 16) p.i did not reveal any differences in lymphocyte or 
myeloid numbers nor their activation. We also detected no differences in the 
differentiation of TH1 or TH17 T cells, arguing that TGFβRII signaling in 
myeloid cells during immune priming is expendable. We generated chimeric 
mice to further confirm that moDCs had a crucial role in determining EAE 
severity. Reconstitution of LysM-TGFbr2 BM into irradiated LysM-TGFbr2 or 
WT mice phenocopied the EAE severity during the persistent phase. In 
contrast, when WT BM was transferred to irradiated LysM-TGFbr2 mice they 
displayed similar clinical EAE as WT BM transferred into irradiated WT mice. 
These data suggest that the observed increased EAE severity in LysM-
TGFbr2 mice is dependent on TGFβr2-deficency in circulating monocytes and 
specifically in moDCs. 
 
4.3.2 TGFβRII-deficiency in moDCs enhances TH1-responses  
Our analysis of the brain during the persistent phase indicated that there were 
higher frequencies of moDCs and T cells in LysM-TGFbr2 mice. Further 
analysis of the T cell compartment revealed significantly increased numbers 
of IFN-γ-producing CD4+ T cells in the CNS with a decrease of IL-17-
producing T cells. However, we did not detect any differences in IFN-γ+IL-17+ 
double-positive T cells, nor any alterations in the numbers of Tregs, indicating 
that TH1 cells had an important role in the persistent phase of EAE in LysM-
TGFbr2 mice.  
An important factor for the differentiation of TH1 cells is IL-12. We thus 
addressed if TGFβ regulated IL-12 secretion from macrophages and DCs in 
LysM-TGRbr2 mice. We generated BM-derived macrophages and DCs by 
using M-CSF or GM-CSF, respectively. Stimulation of macrophages and DCs 
with LPS induced IL-12 secretion from both LysM-TGFbr2 and WT cells. 
However, TGFβ was able to attenuate the LPS-induces IL-12 secretion in WT 
macrophages and DCs, but not in cells from LysM-TGFbr2. We next 
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developed an in vitro APC-T cell reactivation assay to further investigate if 
TGFβ had an important role in the regulation of TH1 cells by limiting the 
production of IL-12 from DCs (Fig. 13A). We co-cultured sorted CD4+ T cells 
from day 7 iLNs of MOG-immunized WT mice with BM-derived DCs from WT 
or LysM-TGFbr2 mice. The DCs were pre-stimulated with LPS in the 
presence or absence of TGFβ and then later co-cultured with iLN-derived 
CD4+ T cells and MOG35-55 peptide for 3 days. Analysis of the CD4+ T cells 
after 3 days revealed that TGFβ-signaling in moDCs indeed regulated the 
differentiation of TH1 cells. We found that IFN-γ+ T cell frequencies were 
significantly reduced when T cells were co-cultured with LPS-TGFβ-stimulated 
WT DCs, but not when co-cultured with stimulated DCs from LysM-TGFbr2 
mice (Fig. 13B and C).  
 
 
Figure 13 | Loss of TGFβ  signaling in APCs polarizes T cells to produce IFN-γ . (A) 
Experimental design and setup for the re-activation assay. (B) Intracellular staining of CD4+ T 
cells from day 7 MOG-immunized iLNs co-cultured with stimulated BM-derived DCs for 3 
days. (C) Soluble IFN-γ was measured from the co-cultures 
 
4.3.3 IFN-γ regulates ROS production in moDCs during EAE 
The mechanisms underlying myelin and axonal damage induced by the 
immune cells in MS and EAE are still not very well understood and many 
models have been proposed. It is considered that radicals from the ROS 
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pathway might have an important role in inducing tissue damage during 
inflammation. However, it is important to remember that physiological 
concentrations of ROS are important for many functions during homeostasis 
and immune defense, such as cellular respiration and elimination of 
pathogens. These processes are also regulated, exposure of electrophiles or 
ROS activating nuclear factor E2 related factor 2 (Nrf2) that in turn activates 
antioxidant enzyme gene transcriptions such as superoxide dismutase, 
glutathione peroxidases, peroxiredoxins, catalase and NAD(P)H: quinone 
oxidoreductase 1223-227. The proposed model is that high amounts of ROS 
during EAE and MS that overpower the antioxidant capacity will result in 
tissue damage such as modifications of lipoproteins and proteins in the cell 
membranes. High amounts of ROS can also induce oxidative stress in the 
tissue cells that will result in mitochondrial injury and DNA damage228. High 
levels of radicals have been demonstrated in cerebrospinal fluid from patients 
with MS and oxidative damage to cellular membrane lipids have been 
detected in MS lesions229,230. Inflammatory macrophages and moDCs are 
important sources of ROS during CNS inflammation. NOX-derived oxidative 
burst from phagocytes is also associated with tissue damage in MS and 
EAE228,231-233.  
We investigated if TGFβ signaling in moDCs was important for the 
regulation of ROS during EAE since we detected increased numbers of 
activated moDCs and severe demyelination in LysM-TGFbr2 mice. Analysis of 
NOX subunits and iNOS gene expression in CNS on day 28 of EAE indicated 
that the expression of the Nox2 gene was upregulated in LysM-TGFbr2 mice. 
Sorting of different myeloid cell populations revealed that the highest 
expression of Nox2 was indeed in moDCs and not in resident microglia or 
infiltrating neutrophils, which we later confirmed by immunohistochemistry. 
We also detected increased ROS activity in LysM-TGFbr2 mice during the 
persistent phase of EAE by employing DCFDA staining of the spinal cord at 
day 28 post-immunization. To further establish the importance of ROS 
synthesis from moDCs in LysM-TGFbr2 mice we measured Nox2 mRNA 
expression in BM-derived DCs after they had been stimulated with LPS in the 
presence or absence of TGFβ. We determined that TGFβ regulated the 
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expression of Nox2 mRNA in BM-derived DCs. However, TGFβ did not 
decrease ROS production from LPS-stimulated BM-derived DCs measured by 
fluorescent dihydrorohadmine-123 (DHR123). TGFβ only decreased ROS 
production from WT BM-derived DCs when IFN-γ was included as a co-
stimulus (Fig. 14). These results thus indicate that TGFβ can regulate LPS-
IFN-γ-induced ROS production by DCs in WT mice, but not in LysM-TGFbr2 
mice.  
These data together indicate that TGFβ regulates the production of IL-12 
from moDCs that is important for the differentiation of TH1 cells during the 
persistent phase of EAE. Furthermore, IFN-γ secretion from these TH1 cells in 
combination with TLR stimulation further activates moDCs to produce and 
release ROS, a process that also was regulated by TGFβ. ROS was 
associated with enhanced demyelination during the persistent phase of EAE 
in LysM-TGFbr2 mice. 
 
Figure 14 | IFN-γ  and TGFβ  regulates ROS-production in moDCs during EAE.  
White bars: WT, black bars: LysM-TGFbr2 
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4.4 Study IV: The role of neutrophils in the regulation of adaptive 
immunity during emergency granulopoiesis. 
 
 
  
Background   
Neutrophils are important innate immune effector cells during acute and chronic 
inflammation. Deregulation of neutrophil cell counts during inflammation can induce a 
state of emergency granulopoiesis to maintain sufficient peripheral neutrophil numbers. 
Extensive research has been performed to understand the role of neutrophils in innate 
immunity during inflammation and emergency granulopoiesis. However, the role of 
neutrophils in the regulation of adaptive immunity during emergency granulopoiesis is 
not very well studied. 
 
Hypothesis   
Neutrophils regulate lymphocyte activation during immune priming in the draining lymph 
nodes. 
 
Methods   
We generated mice in which diphtheria toxin unit A was selectively expressed in LysM+ 
cells (LysM-DTA). Analysis of cellular composition and immune function were conducted 
in both steady state and following adjuvant-induced pro-inflammatory activation. The 
mechanism of action of the observed effect was dissected through a combination of use 
of additional gene-deleted mouse strains, antibody-mediated cell depletion and 
antibody-mediated protein neutralization. The clinical significance of our model was 
examined using an experimental model of systemic lupus erythematosus (SLE).  
 
Results   
LysM-DTA was specifically neutropenic in steady state, but exhibited emergency 
granulopoiesis and extensive neutrophilia in draining lymph nodes following adjuvant-
induced inflammation. Lymph node recruited neutrophils produced BAFF in a G-CSF-
dependent manner, which triggered plasma cell formation and elevated antibody 
production. This mobilization was facilitated by increased CXCL1/CXCL2 expression 
and overlapped with increased numbers of IL-17-producing CD4+ T cells. G-CSF 
neutralization and neutrophil starvation in turn significantly diminished plasma cell 
formation. In the context of B cell-driven autoimmunity, induced neutropenia in SLE mice 
increased plasma cell numbers and serum anti-DNA antibodies.  
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4.4.1 Induced neutropenia in LysM-DTA mice 
Neutrophils have primarily been regarded as the first responding innate 
effector cells during inflammation. Their effector functions include the 
production and release of pro-inflammatory cytokines and chemokines, 
degranulation and secretion of anti-microbial peptides16,234-236. Neutrophils 
recruit inflammatory monocytes to the site of inflammation and they also have 
an important role during the resolution of inflammation. Apoptotic neutrophils 
release ‘eat-me’ signals to the tissue macrophages that upon phagocytosis 
will develop an M2-like phenotype that is associated with the release of TGFβ 
and IL-10.  
Investigators have been using genetic tools such as gene-deficient 
mice, or molecular tools such as antibodies that neutralize neutrophil-released 
proteins, in order to understand and study the functions of neutrophils in vivo.  
Furthermore, neutrophil generation and blood counts also regulate their 
functions. It has been reported that neutrophil blood counts follow the 
circadian rhythm and that modulation of neutrophil circulating numbers has an 
impact on acute inflammation237,238. Live infections or adjuvant immunization 
can also modulate generation and release of neutrophils from the BM, a state 
defined as emergency granulopoiesis75,239. One way to study neutrophils is to 
induce neutropenia. It has been reported that neutrophils migrate to the LNs 
minutes after adjuvant provocation and depletion of these early neutrophils, 
by anti-Ly6G antibodies or by using G-CSFR deficient-mice, enhanced 
antigen presentation by APCs and increased T cell activation21,22. Another 
study used an N-ethyl N-nitrosourea (ENU) mutagenesis strategy and 
generated a neutropenic mouse strain19. They identified that mature 
neutrophils were required both in the BM and in the periphery for NK cell 
development. However, none of these studies had any signs of emergency 
granulopoiesis in their respective models.  
We generated a neutropenic model in order to first investigate the role 
of neutrophils in the regulation of T and B cells. To achieve this we crossed 
LysM-Cre mice with Rosa26-stopflox-DTA mice and obtained a novel mouse 
strain called LysM-DTA. Analysis of the blood, spleen and BM in LysM-DTA 
mice clearly indicated neutropenia with around 85% reduction of neutrophils 
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(Fig. 15). However, as mentioned earlier in study III, LysM is also expressed 
in monocytes and macrophages. Interestingly, we did not see any differences 
in monocyte or any major macrophage populations in LysM-DTA mice 
compared to in WT mice. Analysis by flow cytometery and 
immunohistochemistry revealed that splenic red pulp macrophages, marginal 
zone macrophages and metallophilic macrophages were all intact in LysM-
DTA mice. Further analysis of other myeloid cells such as DCs and 
eosinophils but also different macrophage populations in the brain, 
peritoneum, liver, skin and gut did not reveal any differences between LysM-
DTA and WT mice.  
 
 
Figure 15 | Drastic reduction of neutrophils in LysM-DTA mice. Neutrophils (CD11b+Ly-
6G+) were analyzed in spleen, BM and blood. 
 
One explanation for this could be the fact that Cre recombination is never 
100% efficient. For instance, recombination in peritoneal macrophages is 
around 80-90% based on YFP expression in LysM-CRE x Rosa26-stopflox-
EYFP mice. The surviving non-recombined 10-20% macrophages are enough 
for the organ to repopulate itself during development and a similar mechanism 
can be applied for monocytes. However, neutrophils do not have peripheral 
progenitors, cannot proliferate at a mature stage and thus are dependent on 
BM progenitors for their generation. Furthermore, LysM is expressed relatively 
late during neutrophil maturation and the recombination rate of Cre in 
! 26!
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neutrophils is around 90-95%, indicating high expression of LysM. This 
severely limits the generation of neutrophils in LysM-DTA mice and could be 
the reason for neutropenia but normal homeostasis in other myeloid 
populations such as monocytes and macrophages.  
 
4.4.2 Emergency granulopoiesis and neutrophil recruitment 
We next wanted to investigate the immunological consequences of 
neutropenia in LysM-DTA mice during induced inflammation. We thus 
immunized the mice s.c with CFA and analyzed innate and adaptive immune 
functions. We first noticed splenomegaly in LysM-DTA mice that was already 
evident at day 7 post-immunization (p.i.) (Fig. 16A). We also detected signs of 
lymphadenopathy at this timepoint, but the size of the draining iLNs was 
larger at day 14. We speculated that this could be due to emergency 
granulopoiesis, a triggered response due to neutropenia. Analysis of the 
serum displayed drastically enhanced levels of G-CSF in LysM-DTA 
compared to in WT mice (Fig. 16B). Another feature of emergency 
granulopoiesis is the accumulation and proliferation of myeloid progenitor 
cells in the spleen. Analysis of the spleen in LysM-DTA mice revealed a 2-fold 
increase in CMPs and a 4-8-fold increase in GMPs in comparison to WT 
spleens. The majority of the cells in the spleen were CD11b+ but lacked 
markers for CMP/GMP progenitors such as C-kit or the neutrophil marker Ly-
6G, indicating that these cells were caught in a stage between GMPs and 
mature neutrophils (Fig. 16C). Nonetheless, adjuvant-immunized LysM-DTA 
mice were still neutropenic in blood and BM throughout the 14 days of 
analysis despite the clear signs of emergency granulopoiesis.  
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Figure 16 | Emergency granulopoiesis is induced in LysM-DTA mice after CFA 
provocation. (A) BM, spleen and iLNs 7 days p.i. (B) Serum G-CSF levels in LysM-DTA and 
WT mice after CFA immunization. (C) C-kit+ myeloid progenitors in the spleen of WT and 
LysM-DTA mice 7 days after CFA immunization.  
 
It has been reported that neutrophils migrate to inflamed LNs and that 
this recruitment is divided into two phases22. The first neutrophil wave in WT 
mice was evident at 2 hours p.i. and localized in the LN cortex. The second 
wave of neutrophils was evident between day 7 and 14 but were confined 
instead to the LN paracortex. LysM-DTA mice lacked the first neutrophil wave 
but remarkably displayed a drastic 20-fold higher neutrophil influx into the LN 
paracortex during the second wave compared to in WT mice (Fig. 17). We 
hypothesized that it was a specific recruitment of neutrophils to the iLNs 
regulated by neutrophil-attracting chemokines. We observed a drastic 
increase of CXCL1 and CXCL2 mRNA in iLN cells in LysM-DTA compared to 
in WT mice. A key regulator for the induction of CXCL1, CXCL2 and G-CSF 
secretion by endothelial cells is IL-17. This cytokine is produced by TH17 cells 
locally in the LNs and can thus recruit neutrophils to the tissue89. However, a 
recent study has reported that the induction of G-CSF is independent of IL-17 
but is dependent on TLR4 signaling at the site of inflammation240. ! 27!
Figure 2 
 
  
A B 
C 
WT LysM-DTA 
 56 
 
Figure 17 | Neutrophils are recruited to the iLNs after CFA immunization. Left: neutrophil 
recruitment to the iLN over time. Right: immunohistochemistry of iLNs (C: Cortex, PC: 
paracortex). 
 
 
4.4.3 Neutrophil regulation of T cell differentiation and B cell activation 
We next wanted to address if this deregulation in neutrophil LN recruitment 
affected T cell differentiation and B cell activation. There is already prominent 
evidence that neutrophils regulate T cell activation in the LNs, but if 
neutrophils regulate the differentiation program in T cells has not been 
previously reported. Analysis of iLNs in LysM-DTA mice at day 7 p.i. revealed 
increased numbers of IL-17-producing T cells compared to in WT mice. This 
increase of TH17 cells was associated with the specific recruitment of 
neutrophils to the iLNs at day 7 (Fig. 18A). As mentioned earlier, some of the 
important gene targets of IL-17 are CXCL1, CXCL2 and G-CSF, which could 
explain the neutrophil recruitment phenomenon241,242. We could also detect 
increased production of IFN-γ in CD4+ T cells at day 14 p.i. in LysM-DTA 
compared to in WT mice.   
How do the T cells sense the loss of or the need for neutrophils? 
Earlier studies have demonstrated that neutrophils have the ability to regulate 
the antigen presentation capacity of APCs21, and neutrophils can also 
specifically eliminate APCs in the LNs88. However, this does not explain the 
specific T cell differentiation into TH17. The answer could be in the tissue 
where the initial inflammatory trigger occurs, at a time point where there are 
no or low numbers of circulating neutrophils in LysM-DTA mice. The s.c-
! 28!
Figure 3 
 
  
! 28!
Figure 3 
 
  
 57 
injected adjuvant will activate tissue macrophages and DCs to produce 
neutrophil-attracting chemokines and pro-inflammatory cytokines such as IL-
23. The ingestion of apoptotic neutrophils by tissue APCs will in turn suppress 
the production of IL-23 and thereby reduce the stimulus for TH17 
differentiation243. However, this suppression of APCs does not occur in LysM-
DTA mice due to the neutropenic state during the early phase of inflammation.  
 
 
Figure 18 | Enhanced numbers of IL-17-producing T cells and plasma cells in LysM-DTA 
iLNs. (A) IL-17 and IFN-γ production by CD3+CD4+ T cells in the iLNs. (B) Analysis of 
B220+CD138- B cells and B220-CD138+ plasma cells in the iLNs. (C) Immunofluorescent 
staining of iLN at day 14 p.i. visualizing plasma cells (green, CD138) and neutrophils (red, Ly-
6G). 
 
Moreover, we observed interesting alterations in the B cell compartment in the 
iLNs. We detected a 4-fold increase in numbers of B cells and a striking 25-
fold increase in numbers of plasma cells in LysM-DTA mice at day 14 p.i. 
compared to in WT mice (Fig. 18B). Examination by immunofluorescent 
staining revealed that the recruited neutrophils at day 14 p.i. resided close to 
plasma cells in the paracortex and medulla of the iLNs (Fig. 18C). We also 
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confirmed that the CD138+ cells were indeed bona fide plasma cells through 
their staining of intracellular IgG.  
We thus speculated that recruited neutrophils had a role in the massive 
generation of plasma cells in the iLNs of LysM-DTA mice. A recent report has 
identified ‘B cell helper’ neutrophils in mice and humans that promote T cell-
independent innate B cell activation in the marginal zone of the spleen23. 
However, our model is based on T cell-dependent follicular B cell activation 
during emergency granulopoiesis in the draining LNs. To further confirm that 
our model was not an intrinsic phenomenon only occurring in LysM-DTA mice 
we took advantage of antibody-mediated depletion of neutrophils that also 
induces emergency granulopoiesis244. In agreement with our findings in LysM-
DTA mice, transient anti-Ly6G-mediated neutrophil depletion during 14 days 
p.i. induced increased numbers of B cells, plasma cells, TH17 cells and 
neutrophilia in the iLNs of anti-Ly6G treated WT mice in comparison to 
isotype-treated WT mice. 
Taken together, these data indicate that early neutropenia induces 
emergency granulopoiesis and specific differentiation of T cells into the TH17 
phenotype, which could be due to enhanced IL-23 production by emigrated 
tissue APCs. Enhanced CXCL1 and CXCL2 expression in LysM-DTA recruits 
increased numbers of neutrophils into the iLNs that reside close to B cells and 
plasma cells in the paracortex and medulla. 
 
4.4.4 Neutrophil-mediated B cell activation is regulated by G-CSF  
Since LysM-DTA mice had increased numbers of plasma cells in the iLNs we 
next wanted to investigate if neutrophils in LysM-DTA mice directly regulated 
B cell activation and plasma cell formation. A key factor for B cell activation is 
the cytokine BAFF and it has been reported that human neutrophils can 
produce this cytokine in vitro98. We therefore sorted neutrophils from the iLNs 
at day 14 from both LysM-DTA and WT mice p.i. We detected a significantly 
higher expression of BAFF mRNA in sorted LysM-DTA neutrophils compared 
to sorted WT neutrophils. Moreover, the average expression of BAFF was 
lower in the neutrophil-depleted fraction, indicating that neutrophils are an 
important source of BAFF in the iLNs. G-CSF has been suggested to be 
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important for the intracellular synthesis of BAFF in neutrophils and a 
secondary pro-inflammatory stimulation triggers the release of BAFF by 
neutrophils99. We sorted WT BM neutrophils and stimulated them with G-CSF 
together with either GM-CSF, IL-17, IFN-γ, LPS, IL-18 or CXCL2 for 24 hours. 
Analysis of the supernatants revealed that G-CSF alone did not induce the 
release of BAFF from neutrophils. However, BAFF was detected when 
neutrophils had been stimulated with G-CSF combined with either GM-CSF, 
IFN-γ, LPS or CXCL2, all factors that are present in the microenvironment of 
the inflamed LN (Fig. 19A).  
 
 
Figure 19 | The release of BAFF from neutrophils is G-CSF-dependent (A) BM-sorted 
neutrophils were stimulated for 24 hours with the respective stimuli (B) Analysis of plasma 
cells and neutrophils in iLNs at 14 days p.i. in WT, LysM-DTA and GCSFR-/- mice treated with 
anti-GCSF or isotype control. 
 
Furthermore, we treated CFA-immunized LysM-DTA mice with G-CSF 
neutralizing antibody every second day for 14 days to limit the ‘B cell helper’ 
! 31!
Figure 6 
 ! 31!
Figure 6 
 
A 
B 
 60 
functions of neutrophils in vivo, which indeed limited plasma cell formation 
and neutrophil influx in the iLNs in anti-GCSF treated mice in comparison to 
isotype-treated controls (Fig. 19B). These results were also reproduced in 
CFA-immunized G-CSFR deficient mice (GCSFR-/-). Taken together, this 
uncovers the potential and importance of emergency granulopoiesis in 
increasing G-CSF systemically for the survival and effector functions of 
neutrophils.  
The clinical outcome of LysM-DTA mice following adjuvant provocation 
has many similarities to Felty’s syndrome (FS) in humans245. FS is defined by 
the coexistence of rheumatoid arthritis, lymphadenopathy, splenomegaly and 
neutropenia. FS has also been associated with other autoimmune diseases 
such as systemic lupus erythematosus (SLE). Among various indications of 
SLE, about half of the patients demonstrate some degree of neutropenia246. 
Increased B cell activity is also evident in these patients, with autoantibodies 
against neutrophil antigens and G-CSF having been reported247,248. 
Interestingly, irrespective of the presence or absence of autoantibodies 
against G-CSF, neutropenic FS and SLE patients have increased G-CSF 
levels. FS patients also have hyperplastic and active germinal centers in the 
enlarged spleen and LNs with neutrophil and macrophage infiltrates249,250. 
The association of neutropenia, exaggerated serum levels of G-CSF and 
increased B cell activation with autoimmunity led us to address whether 
induced neutropenia could enhance or accelerate SLE. We took advantage of 
hybrids between the New Zealand White and New Zealand Black strains 
(NZB/WF1) that represent a spontaneous SLE mouse model with pathological 
anti-DNA antibodies. The NZB/WF1 model has many lupus-like symptoms 
such as splenomegaly, lymphadenopathy, elevated serum autoantibodies and 
immune complex-mediated glomerulonephritis251. The spontaneous 
inflammation initiates when the mice are around 5-6 weeks of age.  
We injected anti-Ly-6G or rat isotype control three times weekly for a 
month in 5 week old female NZB/WF1. Analysis of the spleen revealed 
increased numbers of both B cells and plasma cells in anti-Ly-6G treated mice 
in comparison to in isotype-treated mice. We also detected increased 
production of both IFN-γ and IL-17 by CD4+ T cells. Furthermore, 
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measurement of serum antibodies revealed increased anti-DNA titers in 
neutrophil-depleted NZB/WF1 mice. These observations confirm that 
deregulation of neutrophils can enhance B cell-dependent autoimmunity as 
observed in SLE. 
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5 Concluding remarks and future perspectives  
 
In this thesis the role of macrophages, DCs and neutrophils in the regulation 
of adaptive immunity during inflammation and autoimmunity has been studied. 
I have evaluated their regulatory properties both in the secondary lymphoid 
organs and in the targeted organs. The direct effects of innate myeloid cells in 
the activation of the adaptive immune system are well studied. However, the 
regulatory capacity of the myeloid compartment during inflammatory 
responses is still today not very well understood.  
 
I have investigated different activation pathways in macrophages in study I 
and II. We generated BM-derived macrophages or extracted adult microglia 
and stimulated these cells with several activation factors to explore their 
immunomodulatory, wound-healing and homeostatic properties. Various M2-
stimulations such as IL-4, IL-10 or TGFβ had the ability to deactivate 
macrophages, induce a state of immunosuppression or change their 
phagocytic activity. We reported for the first time that M2 macrophages could 
protect NOD mice from developing T1D in study I. However, we and others 
have shown that macrophages have a remarkable ability to quickly adapt to 
environmental signals and thus adapt to new situations. We reported that 
recovered M2r macrophages that had been transferred to NOD mice retained 
their M2 markers such as PD-L2, but also upregulated the M1 marker CD86. 
This indicates that M2r macrophages are relatively stable but still have the 
ability to adapt to the inflamed pancreas. We could also describe a TGFβ-
dependent immunosuppression by the transferred M2 macrophages by 
evaluating the T cell proliferative potential in vitro and ex vivo. However, the 
unaltered T cell infiltration to the pancreas visualized by OPT and the T cell 
activation data did not fully explain the protective role of M2r macrophages in 
T1D pathogenesis. We speculated that the wound-healing and homeostatic 
properties of M2r macrophages could enhance β-cell survival and 
proliferation. Other research groups have partly confirmed these speculations 
but further investigation is needed to fully understand the mechanism of 
action. Similar to the findings in study I, we found in study II that M2 
microglia and M2 macrophages had the ability to significantly attenuate 
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disease severity during the late phase of EAE. We could also detect lower T 
cell activity in the CNS and signs of lower degree of demyelination. We 
believe that M2 macrophages or microglia could have beneficial properties for 
wound-healing and remyelination, as the effects were important during the 
resolution phase. 
Our findings in study I and II define the role of M2 macrophages in 
immunomodulation during inflammatory diseases such as autoimmune T1D 
and EAE. However, it should be further investigated whether M2 
macrophages could be used as a cell therapy in autoimmunity. My colleague 
Dr. Mia dedicated a part of his Ph.D thesis to confirm that human monocyte-
derived macrophages could obtain similar M2 properties to the murine 
counterparts, even those recovered from MS patients252. It would be 
interesting to investigate if epigenetic changes of M2 macrophages could 
enhance their phenotypical stability and hence ‘lock-in’ the M2 phenotype. 
Furthermore, I think it would be more beneficial, based on safety and cost 
efficiency, to develop and discover small molecules that can target 
macrophages in vivo and modulate their activation status into the M2 
phenotype in settings of autoimmune disease.   
 
During our investigation in study I and II, we discovered TGFβ-dependent 
immunosuppressive properties of macrophages. The regulatory functions of 
TGFβ-stimulated macrophages have been reported to be mediated by IL-10 
and TGFβ in vitro. However, the TGFβ-induced immunomodulation by 
macrophages needed to be further investigated. We therefore decided in 
study III to generate mice in which the TGFβ receptor, TGFβRII, was 
specifically deleted in monocytes and macrophages in order to determine the 
role of TGFβ in these cells in vivo during autoimmunity. We took the 
advantage of mice expressing Cre recombinase under the LysM promoter, a 
gene that is expressed in phagocytes such as neutrophils, monocytes and 
macrophages. These mice were then crossed to TGFbr2flox/flox mice and we 
obtained LysM-TGFbr2 mice. Induction of autoimmune neuroinflammation in 
LysM-TGFbr2 mice revealed a more severe disease course during the 
persistent phase of EAE in comparison to littermate control mice. This 
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indicated that TGFβ had an important role in the initiation of the resolution 
phase and not during priming of the immune response. Furthermore, the EAE 
severity was associated with increased accumulation of T cells and moDCs. 
Interestingly, microglia still had functional expression of the TGFβR2 based on 
mRNA expression, only monocytes and moDCs were deficient for the 
receptor. I personally believe that moDCs could also be defined as 
inflammatory monocyte-derived macrophages as there is no specific maker or 
function that can separate them from DCs. Nevertheless, TGFβ had a strong 
inhibitory effect on the IL-12 production by macrophages and moDCs as 
LysM-TGFbr2-derived macrophages and moDCs produced more IL-12 in 
contrast to their WT counterparts. This was indeed also reflected in the CNS 
with increased numbers of IFN-γ producing CD4+ T cells. The increased IFN-γ 
secretion by T cells further activated the phagocytes in the CNS that 
enhanced their ROS activity, which is associated with severe demyelination, a 
phenomenon we detected in the inflamed LysM-TGFbr2 CNS. The role of TH1 
cells has been somewhat neglected after the finding of pathogenic TH17 cells 
and their effector functions in EAE. This study brings new light into the 
function of TH1 cells and their ability to increase ROS activity in macrophages 
and other phagocytes during the persistent phase of EAE. Further 
investigations should be initiated to understand the role of IFN-γ and TH1 cells 
during the later phases of EAE. We have demonstrated in study I and II that 
TGFβ-stimulated macrophages can induce Tregs in vitro. However, we did not 
detect any significant decrease of Tregs in the CNS of LysM-TGFbr2 mice, 
although we never investigated if the immunosuppressive capacity of the 
Tregs was affected. Another interesting question from study III is to define the 
cell type(s) that are responsible for the secretion of TGFβ at the peak of 
disease. These cells would be interesting drug targets for modulating and 
enhancing TGFβ secretion.  
 
Finally, we addressed the role of phagocytes during the development of 
adaptive immune activation in the draining lymph nodes in study IV. To 
achieve this we crossed LysM-Cre mice with Rosa26-stopflox-DTA mice and 
generated LysM-DTA mice. LysM-DTA mice were neutropenic during steady-
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state without any changes in other phagocyte populations such as 
macrophages and DCs. However, LysM-DTA mice generate emergency 
granulopoiesis with enhanced T, B and plasma cell responses and 
neutrophilia in the draining LNs post CFA-immunization. Increased CXCL1 
and CXCL2 expression in the LN was perceived as a possible factor for the 
recruitment of neutrophils to the draining LNs. It would be interesting to 
investigate if IL-17 is an important upstream inducer of CXCL1 or CXCL2 in 
the LN. Another aspect of IL-17 is the induction of TH17 cells in LysM-DTA 
mice. It has been reported that early antibody-induced neutropenia increases 
IL-23 production by local tissue macrophages and DCs. One could speculate 
if migratory APCs from the site of injection have amplified IL-23 production in 
LysM-DTA mice. We also showed that G-CSF is crucial for neutrophils in the 
activation of B cells. G-CSF-stimulated neutrophils synthesize BAFF and 
release it upon a secondary stimulation such as IFN-γ, GM-CSF or CXCL2, all 
factors present in the draining LN. Our data indicates that enhanced T cell 
responses due to neutropenia in combination with emergency granulopoiesis 
increase the systemic G-CSF level that amplifies B cell activation and the 
generation of plasma cells. It would be interesting to investigate if this model 
is active during prolonged bacterial infections and if manipulation of the 
neutrophil compartment could enhance both the cellular and humoral 
immunity against the pathogen during vaccination.  
 
The studies in this thesis reveal the potential of M2 macrophages in regulation 
of inflammatory responses. I have also elucidated a novel mechanism in the 
regulation of B cell activation by neutrophils. Further investigations should be 
performed to develop possible drug-targets to exploit these different 
pathways. 
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